Lidocaine
Other / unclassified targets GOLT1A, TLR4, TRPV1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZTLIDO | — | 2021-04-08 | fda.gov ↗ |
| Approved | EU (EMA) | Fortacin | — | 2013-11-15 | europa.eu ↗ |
| Label expansion | US (FDA) | ZINGO | — | 2009-01-08 | fda.gov ↗ |
| Label expansion | US (FDA) | XYLOCAINE | — | 1981-02-23 | fda.gov ↗ |
| Label expansion | US (FDA) | LIDOPEN | — | 1976-10-18 | fda.gov ↗ |
| Approved | US (FDA) | XYLOCAINE DENTAL | — | 1948-11-19 | fda.gov ↗ |
Trials 916 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 025 trials | ||||||
| Phase 0 | NCT07709390 | Jun 2026 → Jan 2029 expected | — | Ohio State University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07707557 | Dec 2025 → Jun 2026 overdue | — | Abbasi Shaheed Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06935552 | Jun 2025 → Nov 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06462573 | Sep 2024 → Sep 2026 expected | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06243120 | Mar → Sep 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT07169032 | Jan → Feb 2024 | — | Li Zhen Zhong | Completed | No outcome recorded |
| Phase 0 | NCT05298761 | Dec 2023 → Mar 2024 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT03095404 | Oct 2022 → Aug 2025 | — | McMaster University | Withdrawn | No outcome recorded |
| Phase 0 | NCT05921292 | Jul 2022 → Jan 2024 | chronic ulcer of skin | Omeza, LLC | Completed | No outcome recorded |
| Phase 0 | NCT06293807 | Jun 2022 → Apr 2023 | periodontal disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT05060913 | Nov 2021 → Mar 2022 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT04192773 | Apr 2021 → Dec 2027 expected | tinnitus | D. Bradley Welling, MD, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04583137 | Nov 2020 → Nov 2022 | — | Kfir Siag | Unknown | No outcome recorded |
| Phase 0 | NCT04413799 | Sep 2020 → Dec 2024 | — | George Washington University | Terminated | No outcome recorded |
| Phase 0 | NCT04519463 | Sep 2020 → Sep 2022 | — | Muhamed Masalha | Unknown | No outcome recorded |
| Phase 0 | NCT04774029 | Jan → Apr 2020 | vertebral disorder | Northwell Health | Completed | No outcome recorded |
| Phase 0 | NCT03676725 | Aug 2019 → Mar 2020 | attention deficit-hyperactivity disorder, premenstrual tension | PhenoSolve, LLC | Completed | No outcome recorded |
| Phase 0 | NCT04048278 | Nov 2018 → Nov 2027 expected | malignant pancreatic neoplasm | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 0 | NCT04732104 | Jul 2018 → Jun 2020 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT02955524 | Mar 2018 → Jun 2020 | — | University of Miami | Withdrawn | No outcome recorded |
| Phase 0 | NCT04167189 | Jan 2018 → Mar 2020 | attention deficit-hyperactivity disorder | PhenoSolve, LLC | Completed | No outcome recorded |
| Phase 0 | NCT03145207 | Dec 2016 → Jan 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 0 | NCT03323567 | Jan 2016 → Oct 2017 | temporomandibular joint disorder | Medical University of Silesia | Completed | No outcome recorded |
| Phase 0 | NCT02088866 | Mar 2014 → Aug 2015 | tinnitus | University of California, Davis | Completed | No outcome recorded |
| Phase 151 trials | ||||||
| Phase 1 | NCT06747390 | Apr 2025 → Nov 2026 expected | human papilloma virus infection, oropharynx squamous cell carcinoma | Ryan Carey | Recruiting | No outcome recorded |
| Phase 1 | NCT06310200 | Jan → May 2025 overdue | headache disorder | Wright State University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06462781 | Mar 2024 → May 2025 | migraine disorder | The Cooper Health System | Completed | No outcome recorded |
| Phase 1 | NCT06516861 | Jan → Feb 2024 | — | Arsil Radiansyah | Completed | No outcome recorded |
| Phase 1 | NCT05501600 | Nov 2022 → Nov 2023 | — | Keith M Vogt | Completed | No outcome recorded |
| Phase 1 | NCT05417425 | Sep 2022 → Oct 2023 | ulcer of lower limbs | Omeza, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05343299 | May 2022 → Jun 2023 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05361369 | May 2022 | — | Exeltis Turkey | Completed | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05106400 | Jul 2021 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04979923 | Jul 2021 | acute respiratory distress syndrome | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 1 | NCT05912335 | Jun 2021 → Feb 2022 | tooth disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT04716699 | Jan → Dec 2021 | glioblastoma | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT03177252 | Oct 2020 → Sep 2021 | brain neoplasm | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04784728 | Aug 2019 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03806595 | Jul 2019 → Dec 2020 | migraine disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 1 | NCT05589402 | Jun 2019 → Jun 2026 overdue | spinal cord injury, stroke disorder | University of Texas Rio Grande Valley | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04185194 | Jan 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT04162535 | Nov 2018 → Dec 2023 | colorectal cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT03797703 | Nov 2018 → May 2020 | hemorrhoid | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04319926 | Sep 2018 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03310047 | Oct 2017 → Mar 2018 | — | Nordsjaellands Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04692896 | Sep 2017 → Mar 2018 | — | King Edward Medical University | Completed | No outcome recorded |
| Phase 1 | NCT04320173 | Feb → Mar 2017 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04149938 | Sep → Oct 2016 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04150536 | Jan 2016 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04312750 | Dec 2015 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02593370 | Oct → Nov 2015 | bone disorder | Thomas F. Bendtsen | Completed | No outcome recorded |
| Phase 1 | NCT02460627 | May 2015 → Jan 2017 | — | Northern Orthopaedic Division, Denmark | Unknown | No outcome recorded |
| Phase 1 | NCT03265197 | Mar → Oct 2015 | tinnitus | saad elzayat | Completed | No outcome recorded |
| Phase 1 | NCT02679339 | Jan → Aug 2015 | herpes zoster | Centrexion Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT02241096 | Jan → Sep 2015 | — | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded |
| Phase 1 | NCT03026855 | Jun 2014 → Apr 2016 | chronic ulcer of skin | TotipotentRX Cell Therapy Pvt. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04144192 | Apr → Jul 2014 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02268968 | Oct 2013 → Dec 2014 | — | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01879683 | Jul 2013 → May 2014 | interstitial cystitis | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT01688362 | Nov 2012 → May 2014 | rotator cuff syndrome | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 1 | NCT01541293 | Sep 2012 → Oct 2013 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT01355549 | May 2011 → Nov 2012 | arthropathy, rotator cuff syndrome, spinal cord injury, tendinitis | Kessler Foundation | Completed | No outcome recorded |
| Phase 1 | NCT01463280 | Jan 2011 → Dec 2013 | venous thromboembolism | Klein, Jeffrey A., M.D. | Completed | No outcome recorded |
| Phase 1 | NCT01150565 | Jul 2010 → Sep 2011 | interstitial cystitis | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT00964288 | Jul → Nov 2009 | neuropathy, painful | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT01324843 | Jun 2009 → May 2010 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1 | NCT00686231 | May → Dec 2008 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01425840 | Mar → Nov 2008 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT01054547 | Sep → Dec 2006 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT00566904 | Sep 2006 → Aug 2008 | postherpetic neuralgia | Biomedical Development Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00373893 | Dec 2005 → Feb 2006 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 1 | NCT01355588 | Aug → Sep 2005 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00991848 | Jan 2005 → Jul 2007 | fibromyalgia | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 1 | NCT00308841 | — | — | Suleyman Demirel University | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT06875791 | Dec 2025 → Dec 2026 expected | head and neck squamous cell carcinoma, mucositis | Fundacion Clinica Valle del Lili | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05694858 | Feb 2025 → Dec 2026 expected | cataract, glaucoma | Universiti Kebangsaan Malaysia Medical Centre | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06661902 | Jan 2025 → Jan 2026 | prostate cancer | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT05573191 | Oct → Nov 2022 | — | General Hospital of Ningxia Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05476679 | Sep 2022 → Jun 2023 | — | Raziel Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04026945 | Oct 2019 → Mar 2021 | chronic pain syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 1/2 | NCT03220113 | Jul 2017 → Jul 2018 | migraine with aura, migraine without aura | Corona Doctors Medical Clinics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01654302 | Sep 2013 → Sep 2014 | osteoarthritis, knee | Thomas J. Schnitzer | Completed | No outcome recorded |
| Phase 1/2 | NCT03117166 | Jan → May 2010 | — | Drexel University College of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT00791024 | Nov 2008 → Nov 2009 | — | Ove Andersen | Completed | No outcome recorded |
| Phase 1/2 | NCT01108562 | Feb → Aug 2008 | — | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00977028 | Jan 2005 → Jul 2011 | — | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 1/2 | NCT00540982 | Feb 1997 → May 2010 | lung cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 295 trials | ||||||
| Phase 2 | NCT04414917 | Nov 2026 → Nov 2029 | neuropathy, painful | Rutgers, The State University of New Jersey | Suspended | No outcome recorded |
| Phase 2 | NCT07094542 | Sep 2026 → Nov 2029 expected | impacted teeth, multiple, myofascial pain syndrome | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07700108 | Jun 2026 → Jan 2029 expected | — | Ohio State University | Recruiting | No outcome recorded |
| Phase 2 | NCT07054801 | Jun 2026 → Jan 2027 expected | subarachnoid hemorrhage | Daniel Raper, MBBS | Recruiting | No outcome recorded |
| Phase 2 | NCT07567274 | May → Jul 2026 overdue | tinnitus | Leading Edge Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07268118 | May 2026 → Jun 2027 expected | — | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05729503 | May 2026 | anxiety | University of Calgary | Withdrawn | No outcome recorded |
| Phase 2 | NCT07361549 | Mar 2026 → Dec 2030 expected | migraine disorder | The Cooper Health System | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07273916 | Mar → May 2026 overdue | — | Hexsel Dermatology Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07294118 | Jan 2026 → Jun 2027 expected | acquired aneurysmal subarachnoid hemorrhage, headache disorder, opiate dependence | The University of Texas Medical Branch, Galveston | Recruiting | No outcome recorded |
| Phase 2 | NCT07250867 | Jan 2026 → Jan 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07432399 | Sep 2025 → May 2027 expected | colon carcinoma | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| Phase 2 | NCT07031206 | Jul 2025 → May 2026 overdue | anxiety | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06955923 | May → Aug 2025 | myofascial pain syndrome | David Grant U.S. Air Force Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT07061847 | Mar 2025 → Mar 2027 expected | migraine disorder | Northwell Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06451120 | Jun 2024 → Feb 2027 expected | articular cartilage disorder, osteoarthritis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT05923086 | Jan 2024 → Dec 2025 overdue | ileus | Orexa BV | Recruiting | No outcome recorded |
| Phase 2 | NCT06433713 | Dec 2023 → Mar 2024 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT06109389 | Oct 2023 → May 2024 | migraine disorder | Alexandria University | Unknown | No outcome recorded |
| Phase 2 | NCT05890703 | Jun → Oct 2023 | ecthyma, ulcer of lower limbs | Juerg Hafner | Unknown | No outcome recorded |
| Phase 2 | NCT05737121 | May 2023 → Jun 2026 overdue | interstitial cystitis | Vaneltix Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05783219 | May 2023 → Apr 2024 | overactive bladder | University of Louisville | Completed | No outcome recorded |
| Phase 2 | NCT06862570 | Dec 2022 → May 2023 | pulpitis | 28 Military Dental Centre Lahore | Completed | No outcome recorded |
| Phase 2 | NCT05223075 | Nov 2022 → Feb 2023 | — | Fayoum University | Unknown | No outcome recorded |
| Phase 2 | NCT05335070 | Sep 2022 → Nov 2026 expected | — | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06532162 | Jun 2022 → Aug 2024 | — | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 2 | NCT05365880 | Mar 2022 → Mar 2025 | headache disorder, ischemic stroke | University of Utah | Withdrawn | No outcome recorded |
| Phase 2 | NCT05017246 | Jan 2022 → Jul 2024 | uterine corpus leiomyoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT05777122 | Jan 2022 → Mar 2023 | — | Sadaf Bashir | Unknown | No outcome recorded |
| Phase 2 | NCT05193227 | Oct 2021 → Apr 2026 overdue | — | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2 | NCT05078463 | Sep 2021 → Aug 2022 | thalassemia | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 2 | NCT04650282 | Mar → Apr 2021 | headache disorder, traumatic encephalopathy | University of Michigan | Terminated | No outcome recorded |
| Phase 2 | NCT05906615 | Jan 2021 → Jul 2023 | chronic pancreatitis, malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 2 | NCT04250805 | Oct 2020 → Jan 2024 | cancer, eating disorder | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 2 | NCT04467424 | Jun → Nov 2020 | — | University Hospital of Split | Completed | No outcome recorded |
| Phase 2 | NCT05492669 | Feb 2020 → Jul 2024 | chronic pain syndrome | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03865940 | Nov 2019 → Oct 2023 | trigeminal neuralgia | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03430531 | May 2019 → Jan 2020 | intracranial hypotension | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03865147 | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03578783 | Dec 2018 → May 2021 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03778008 | Dec 2018 → Dec 2019 | stomatitis | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT03343080 | Jul → Oct 2018 | heart disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03560349 | Jul 2018 → Jan 2019 | intracranial hypotension | University of Utah | Withdrawn | No outcome recorded |
| Phase 2 | NCT03825016 | Aug 2017 → Jan 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT03197558 | Jun → Sep 2017 | eustachian tube disorder, otitis media with effusion | Tusker Medical | Completed | No outcome recorded |
| Phase 2 | NCT03386552 | Jun 2017 → May 2018 | infertility disorder | Isifer AB | Unknown | No outcome recorded |
| Phase 2 | NCT03096444 | May → Jul 2017 | — | Gil Yosipovitch | Terminated | No outcome recorded |
| Phase 2 | NCT03054844 | Apr → Oct 2017 | — | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT03047057 | Mar 2017 → Jul 2018 | ileus | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02916940 | Nov 2016 → Feb 2020 | — | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02696720 | May 2016 → Jun 2017 | — | Brugmann University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT02763592 | May 2016 → Mar 2017 | neuropathy, painful | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 2 | NCT02591199 | Sep 2015 → May 2018 | interstitial cystitis | Urigen | Terminated | No outcome recorded |
| Phase 2 | NCT02411110 | May 2015 → Oct 2016 | interstitial cystitis | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02689856 | May → Sep 2015 | hemorrhoid | Citius Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02395042 | Apr 2015 → Jun 2017 | interstitial cystitis, ulcer disease | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02577393 | Apr 2015 → Jun 2022 | esophagitis, lung neoplasm | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01929343 | Jan 2014 → Mar 2016 | cocaine dependence | Bryon Adinoff | Completed | No outcome recorded |
| Phase 2 | NCT02033356 | Jan → Feb 2014 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT01824303 | Mar 2013 → Nov 2014 | interstitial cystitis | Allergan | Terminated | No outcome recorded |
| Phase 2 | NCT01744197 | Jan → Feb 2013 | — | US Oncology Research | Completed | No outcome recorded |
| Phase 2 | NCT01048177 | Dec 2012 → Jun 2014 | vulvodynia | Scripps Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT01544283 | Mar 2012 → Jan 2014 | shoulder impingement syndrome | Injury Care Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01552096 | Dec 2011 → Oct 2013 | inflammatory disease | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| Phase 2 | NCT01690767 | Dec 2011 → Dec 2014 | urinary tract infection | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT01475253 | Nov 2011 → Dec 2012 | interstitial cystitis | Allergan | Terminated | No outcome recorded |
| Phase 2 | NCT01405768 | Jul 2011 → Oct 2012 | dysplasia of cervix | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01360749 | May → Nov 2011 | — | ISDIN | Completed | No outcome recorded |
| Phase 2 | NCT01202487 | Apr 2011 → Jan 2012 | — | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 2 | NCT01314300 | Mar 2011 → Jul 2014 | neuropathy, painful, sickle cell disease | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT01111773 | Jun 2010 → Mar 2011 | disease of the tendon | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01106989 | Jun → Dec 2010 | myofascial pain syndrome | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01115062 | Apr 2010 → Jun 2011 | — | Carol Morreale | Completed | No outcome recorded |
| Phase 2 | NCT01055444 | Mar → Aug 2010 | shoulder impingement syndrome | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01204242 | Aug 2009 → Nov 2018 | breast cancer | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT01155440 | Jun 2009 → Oct 2011 | colon carcinoma, diverticulitis, inflammatory bowel disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2 | NCT00732589 | Aug → Dec 2008 | arthropathy, stroke disorder | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2 | NCT00609323 | Jan → Jul 2008 | postherpetic neuralgia | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00590590 | Oct 2007 → Jun 2009 | vulvodynia | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00508976 | Jun 2007 → Apr 2008 | morbid obesity | Pinnacle Health System | Completed | No outcome recorded |
| Phase 2 | NCT01329796 | Mar 2007 → Jun 2009 | dysmenorrhea, endometriosis | Isifer AB | Completed | No outcome recorded |
| Phase 2 | NCT00811187 | Mar 2007 → Mar 2008 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00589979 | Mar 2007 → Jun 2008 | osteoarthritis, knee | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00450242 | Dec 2006 → Jan 2009 | vulvodynia | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT00321347 | May 2006 → May 2009 | neoplasm | San Diego Hospice & Palliative Care | Withdrawn | No outcome recorded |
| Phase 2 | NCT00317070 | Apr 2006 → Feb 2009 | interstitial cystitis | Nova Scotia Health Authority | Terminated | No outcome recorded |
| Phase 2 | NCT00256542 | Jan → Sep 2006 | interstitial cystitis, pelvis syndrome | Urigen | Completed | No outcome recorded |
| Phase 2 | NCT00258622 | Nov 2005 → Feb 2007 | — | Danish Pain Research Center | Completed | No outcome recorded |
| Phase 2 | NCT00904111 | Aug 2004 → Oct 2005 | chronic pain syndrome | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00904462 | Aug 2004 → Sep 2005 | osteoarthritis, knee | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00132405 | May → Sep 2004 | — | AlgoRx Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00108446 | Oct 2003 → Mar 2006 | irritable bowel syndrome | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00449449 | Sep 2003 → Sep 2006 | infertility disorder | Isifer AB | Completed | No outcome recorded |
| Phase 2 | NCT02218203 | Apr 2003 → Jan 2008 | allesthesia, neuropathy, painful, spinal cord injury | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00372658 | Jul 2002 → Oct 2004 | infertility disorder | 59th Medical Wing | Completed | No outcome recorded |
| Phase 2/324 trials | ||||||
| Phase 2/3 | NCT07445191 | Mar → Jun 2026 overdue | temporomandibular joint disorder | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07315490 | Aug 2025 → Jan 2026 overdue | — | PAEC General Hospital, Islamabad | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT07343128 | Jun → Dec 2025 | fibromyalgia | Sanliurfa Education and Research Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT06740903 | Aug 2024 → Aug 2025 overdue | cholecystitis | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03226626 | Dec 2021 → Jan 2022 | infectious disease with sepsis, thrombotic disease | HK Surgical, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05153785 | Nov 2021 → Jun 2025 | liver cancer, substance-related disorder | Lund University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04648891 | Aug 2021 → Jul 2023 | spasmodic dystonia | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT04741880 | Jun 2021 → Dec 2022 | cancer | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT04901065 | May → Jun 2021 | COVID-19 | Evelyne D.Trottier | Completed | No outcome recorded |
| Phase 2/3 | NCT03967197 | Aug 2019 → Aug 2020 | — | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 2/3 | NCT02801786 | Nov 2018 → Nov 2020 | — | Federal University of Goiás | Unknown | No outcome recorded |
| Phase 2/3 | NCT03725995 | Jun 2017 → Jan 2018 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03109392 | May 2017 → Jun 2018 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT03199417 | May 2017 → May 2018 | osteoarthritis, knee | University of Michigan | Terminated | No outcome recorded |
| Phase 2/3 | NCT03531970 | Aug 2016 → Aug 2017 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02595463 | Nov 2015 → Jun 2024 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2/3 | NCT01955824 | May → Nov 2014 | interstitial lung disease, lung cancer, sarcoidosis, tuberculosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01961739 | Oct 2013 → Mar 2014 | hemorrhoid | University Hospital Dubrava | Unknown | No outcome recorded |
| Phase 2/3 | NCT01384877 | Dec 2011 → Dec 2017 | — | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2/3 | NCT02969733 | Jan 2011 → Sep 2017 | neuropathy, painful | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2/3 | NCT01155167 | Jul 2010 → Aug 2011 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2/3 | NCT01086150 | Oct 2009 → Oct 2015 | diabetic polyneuropathy | Albany Medical College | Completed | No outcome recorded |
| Phase 2/3 | NCT00413127 | Sep 2007 → Mar 2014 | — | University Hospital Muenster | Terminated | No outcome recorded |
| Phase 2/3 | NCT00740285 | Apr 2004 → Apr 2006 | systemic sclerosis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3117 trials | ||||||
| Phase 3 | NCT07274254 | Jul 2026 → Aug 2028 expected | sickle cell disease | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07661758 | Jul → Nov 2026 expected | headache disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT07076641 | Jul 2026 → Jul 2027 expected | digestive system disorder | Ramsay Santé | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07414706 | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07330726 | Jan → Apr 2026 overdue | impacted teeth, multiple | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07299630 | Dec 2025 → May 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07212192 | Nov → Dec 2025 overdue | pregnancy disorder | Phenikaa University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07000760 | Jun 2025 → Jan 2026 | — | Jun Zhang | Completed | No outcome recorded |
| Phase 3 | NCT06769204 | Feb → Aug 2025 overdue | female infertility | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06202989 | Sep 2024 → May 2026 | — | KAZM Pharmaceuticals Inc. | Completed | No outcome recorded |
| Show all 117 trials opens the full record — a long page | ||||||
| Phase 4237 trials | ||||||
| Phase 4 | NCT07566312 | Jan → Apr 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07429292 | Sep → Dec 2026 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07497737 | Aug 2026 → Apr 2027 expected | frozen shoulder | University Hospitals Cleveland Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590830 | Aug 2026 → Sep 2028 expected | — | Rennes University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07691359 | Jul 2026 → Oct 2027 expected | neuropathy, painful, osteoporosis | University Hospital, Clermont-Ferrand | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07552766 | Jun 2026 → Dec 2028 expected | — | Nemours Children's Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07354217 | Jun 2026 → Dec 2030 expected | paroxysmal atrial fibrillation | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07601698 | May → Nov 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07504497 | Apr → Dec 2026 expected | — | Younes Ahmed Younes | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07499154 | Apr 2026 → Dec 2027 expected | acute lung injury, congenital heart disease | The Children's Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Show all 237 trials opens the full record — a long page | ||||||
| Phase not applicable354 trials | ||||||
| — | NCT07627100 | Jun 2026 → Jun 2027 expected | — | Mayo Hospital Lahore | Not yet recruiting | No outcome recorded |
| — | NCT07657260 | Jun → Jul 2026 overdue | — | Xidian University | Recruiting | No outcome recorded |
| — | NCT07612839 | Jun → Aug 2026 overdue | — | Hakan Emirkadı | Not yet recruiting | No outcome recorded |
| — | NCT07607691 | Jun → Oct 2026 expected | bursitis, chronic pain syndrome, frozen shoulder, rotator cuff syndrome | Ankara City Hospital Bilkent | Not yet recruiting | No outcome recorded |
| — | NCT07675616 | May → Dec 2026 expected | lacrimal duct obstruction | Cairo University | Recruiting | No outcome recorded |
| — | NCT07203274 | May → Dec 2026 expected | — | Aalborg University | Not yet recruiting | No outcome recorded |
| — | NCT07488832 | Apr → Nov 2026 expected | — | Ankara City Hospital Bilkent | Recruiting | No outcome recorded |
| — | NCT07267897 | Mar → Jun 2026 overdue | — | Sakarya University | Not yet recruiting | No outcome recorded |
| — | NCT07638254 | Mar → Sep 2026 expected | pulpitis | Autonomous University of San Luis Potosí | Recruiting | No outcome recorded |
| — | NCT07703553 | Feb → Jul 2026 | — | Harran University | Completed | No outcome recorded |
| Show all 354 trials opens the full record — a long page | ||||||
Also used as a comparator or background therapy in 1,085 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 039 trials | ||||||
| Phase 0 | NCT06999057 Comparator | Aug 2026 → Aug 2027 expected | — | University of Central Florida | Recruiting | No outcome recorded |
| Phase 0 | NCT07211399 Background | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded |
| Phase 0 | NCT07675304 Comparator | May → Dec 2026 expected | — | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Recruiting | No outcome recorded |
| Phase 0 | NCT07511400 Comparator | Apr → Jun 2026 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 0 | NCT07408193 Comparator | Mar 2026 → Aug 2027 expected | refractory malignant neoplasm | National and Kapodistrian University of Athens | Recruiting | No outcome recorded |
| Phase 0 | NCT07296653 Comparator | Dec 2025 → Dec 2026 expected | — | National and Kapodistrian University of Athens | Recruiting | No outcome recorded |
| Phase 0 | NCT06824025 Comparator | Feb 2025 → Jan 2027 expected | intracranial hypotension | Minia University | Recruiting | No outcome recorded |
| Phase 0 | NCT06874244 Comparator | Aug 2024 → Jun 2025 | — | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| Phase 0 | NCT06345833 Background | Jul 2024 → Jul 2026 overdue | hemophilia, hemorrhagic disease | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT06607861 Comparator | Jun 2024 → Jun 2026 overdue | — | Minia University | Recruiting | No outcome recorded |
| Phase 0 | NCT05747469 Background | Aug 2023 → Jan 2027 expected | osteoarthritis, hand | Cedars-Sinai Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05935280 Comparator | Jul → Sep 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 0 | NCT05742061 Comparator | Apr → Oct 2023 | osteoarthritis, knee | Benha University | Unknown | No outcome recorded |
| Phase 0 | NCT05486819 Comparator | Aug 2022 → Feb 2023 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05150756 Comparator | Jan → Jul 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT04992572 Comparator | Dec 2021 → Dec 2026 expected | lumbar spinal stenosis | Stanford University | Recruiting | No outcome recorded |
| Phase 0 | NCT05086224 Background | Jul 2021 → Jul 2027 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04630886 Background | Jun 2021 → Jan 2024 | skin neoplasm | Riley McLean | Terminated | No outcome recorded |
| Phase 0 | NCT04377204 Comparator | Jun 2020 → Dec 2022 | — | Our Lady of the Lake Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03658109 Comparator | Sep 2019 → May 2021 | female reproductive organ cancer | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 0 | NCT03445611 Background | Sep → Oct 2019 | osteoarthritis, knee | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 0 | NCT03680885 Comparator | Aug 2019 → Mar 2020 | attention deficit-hyperactivity disorder | PhenoSolve, LLC | Completed | No outcome recorded |
| Phase 0 | NCT03414359 Comparator | Feb 2018 → Mar 2019 | — | University of Arkansas | Completed | No outcome recorded |
| Phase 0 | NCT03243032 Comparator | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02995083 Comparator | Jun 2017 → Jan 2018 | osteoarthritis, knee | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03411330 Comparator | Jan 2017 → Apr 2018 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03140293 Comparator | Sep 2016 → May 2017 | — | Angela Bianco | Completed | No outcome recorded |
| Phase 0 | NCT02825095 Comparator | Aug 2016 → May 2017 | lung neoplasm, pleural neoplasm | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 0 | NCT03616262 Comparator | Jul 2016 → Dec 2019 | complex regional pain syndrome | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| Phase 0 | NCT02786329 Comparator | Jun 2016 → Aug 2022 | colorectal cancer | Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor | Unknown | No outcome recorded |
| Phase 0 | NCT03746418 Comparator | Jan 2016 → Jan 2018 | spondylolisthesis | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT02831374 Background | Oct 2015 → Mar 2016 | impacted teeth, multiple | Linyi People's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04017845 Comparator | Apr 2015 → May 2017 | adenomatous colon polyp, colorectal cancer | Lewai Sharki Abdulaziz, MSc PhD | Completed | No outcome recorded |
| Phase 0 | NCT02427724 Comparator | Apr 2015 → May 2024 | lentigo | Northwestern University | Completed | No outcome recorded |
| Phase 0 | NCT01298310 Comparator | Feb 2011 → May 2012 | Morton neuroma | AstraZeneca | Completed | No outcome recorded |
| Phase 0 | NCT01445756 Comparator | Jul 2010 → Jun 2011 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT00924963 Comparator | Jun 2009 → Jun 2010 | — | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
| Phase 0 | NCT02066818 Comparator | Jan 2008 → Jan 2010 | abscess | East Carolina University | Completed | No outcome recorded |
| Phase 0 | NCT00370799 Comparator | Jan 2007 → Dec 2009 | — | Pain Management Center of Paducah | Completed | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT06653400 Background | Feb 2025 → Sep 2026 expected | pain agnosia, uterine anomalies | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06834854 Comparator | Mar → Aug 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT07248332 Comparator | Jan 2024 → Sep 2025 | acute cholecystitis | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 1 | NCT06564987 Comparator | Jan → Dec 2024 overdue | — | Cleveland Dental Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06631625 Background | Sep 2023 → Sep 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 1 | NCT07248384 Comparator | Jul 2023 → Aug 2025 | neuropathy, painful | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 1 | NCT06703437 Background | Dec 2022 → Feb 2023 overdue | prostate cancer | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05288920 Comparator | Mar → Sep 2022 | lumbar disk disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 1 | NCT05274984 Comparator | Jan → Mar 2022 | — | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT05141864 Comparator | Mar → Jun 2021 | — | Universidade do Vale do Sapucai | Completed | No outcome recorded |
| Phase 1 | NCT04106050 Comparator | Sep 2020 → Jan 2022 | diabetic polyneuropathy | Biogen | Withdrawn | No outcome recorded |
| Phase 1 | NCT04819581 Comparator | Aug 2019 | — | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05267938 Background | Aug → Oct 2019 | mouth disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT03880409 Comparator | Feb → Sep 2019 | — | Taibah University | Completed | No outcome recorded |
| Phase 1 | NCT04051203 Comparator | Feb 2019 → Dec 2023 | headache disorder, neuralgia | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT02401074 Background | Nov 2018 → Jun 2020 | asthma | Lu Yuan Lee | Withdrawn | No outcome recorded |
| Phase 1 | NCT03566329 Comparator | Jul 2018 → Dec 2019 | hypertensive disorder | Ahmed Mohamed ELbadawy | Unknown | No outcome recorded |
| Phase 1 | NCT03576508 Background | Jun → Sep 2018 | osteoarthritis, knee | Centrexion Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03313336 Comparator | Oct → Nov 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02240407 Background | Oct 2017 → Aug 2021 | glycogen storage disease II | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT02951377 Background | Oct 2017 → Jan 2020 | lumbar disk disease, radiculopathy, sciatica | University of Alberta | Terminated | No outcome recorded |
| Phase 1 | NCT03180125 Background | Aug → Oct 2017 | carpal tunnel syndrome | Assiut University | Completed | No outcome recorded |
| Phase 1 | NCT03502395 Comparator | Apr 2017 → Jan 2018 | breast cancer | Assiut University | Completed | No outcome recorded |
| Phase 1 | NCT03268278 Comparator | Apr 2017 → Jul 2018 | — | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02838758 Comparator | Jul 2016 → Jun 2018 | Morton neuroma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1 | NCT02684786 Background | Jul 2016 | pulmonary arterial hypertension | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 1 | NCT03441841 Comparator | Feb → Mar 2016 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT02644421 Comparator | Nov 2015 → Jul 2017 | radiculopathy, sciatica | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03325803 Background | Sep 2015 → Sep 2016 | actinic keratosis | Dong-A University | Completed | No outcome recorded |
| Phase 1 | NCT02733393 Background | Sep 2015 → Sep 2017 | shoulder impingement syndrome | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT02308748 Comparator | May → Jun 2014 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT01996384 Background | Nov 2013 → Mar 2016 | vulvitis, vulvodynia | Oregon College of Oriental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01916642 Comparator | Apr → Jun 2013 | — | West China Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01688518 Comparator | Sep → Nov 2012 | — | CRI Lifetree | Completed | No outcome recorded |
| Phase 1 | NCT01494636 Background | Oct 2011 → Mar 2012 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01240148 Comparator | Dec 2010 → Mar 2011 | neuropathy, painful | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04247230 Comparator | Sep → Oct 2008 | — | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02158039 Background | Jun 2004 → Sep 2015 | cystic, mucinous, and serous neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/225 trials | ||||||
| Phase 1/2 | NCT07396129 Comparator | Aug → Dec 2026 expected | neuropathy, painful | Pontificia Universidad Catolica de Chile | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07256834 Comparator | Nov → Dec 2025 overdue | — | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06983886 Background | May 2025 → Jun 2026 overdue | — | Ramathibodi Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06820164 Background | May 2025 → Jan 2027 expected | lipoma | West Virginia University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06431165 Comparator | Mar 2024 → Mar 2025 | — | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT06362915 Comparator | Jan → Jul 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT06457100 Comparator | Nov 2023 → Jun 2024 | chronic rhinosinusitis | The Second People's Hospital of Huai'an | Unknown | No outcome recorded |
| Phase 1/2 | NCT05585112 Comparator | Oct → Dec 2022 | — | Latakia University | Completed | No outcome recorded |
| Phase 1/2 | NCT05289804 Comparator | Sep 2022 → Dec 2025 | cognitive disorder, cognitive impairment with or without cerebellar ataxia | University of Dublin, Trinity College | Completed | No outcome recorded |
| Phase 1/2 | NCT05445921 Background | Sep → Dec 2022 | anosmia, olfactory nerve disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT05200884 Comparator | Jan → Mar 2022 | — | Latakia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04773093 Comparator | Jan → Dec 2021 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02607488 Comparator | Nov 2020 → Dec 2022 | obesity disorder | Mansoura University | Suspended | No outcome recorded |
| Phase 1/2 | NCT04535089 Comparator | Oct 2020 → Oct 2021 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1/2 | NCT04061265 Comparator | Aug 2019 → Jan 2020 | — | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT03781908 Background | Jan → Dec 2019 | thoracic cancer | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03453151 Background | May 2018 → Jun 2019 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT03254394 Comparator | Sep 2017 → Sep 2020 | chemotherapy-induced neuropathy, colorectal cancer, neuropathy, painful | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT02872012 Comparator | Mar 2016 → Jun 2018 | — | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT02462681 Comparator | May 2015 → Dec 2016 | chronic pain syndrome | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT02300727 Comparator | Feb 2015 → Oct 2018 | mucositis | Amy Beres | Terminated | No outcome recorded |
| Phase 1/2 | NCT01836614 Comparator | Jan 2015 → Mar 2018 | large intestine disorder | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02301052 Comparator | Sep → Nov 2014 | hemorrhoid | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02065947 Background | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01186549 Comparator | Aug → Oct 2010 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 290 trials | ||||||
| Phase 2 | NCT07068243 Background | Sep 2026 → Feb 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07487246 Background | Jun 2026 → Apr 2027 expected | — | Rush University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07680504 Background | Jun 2026 → Jun 2029 expected | frozen shoulder | Nantes University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06923787 Comparator | Feb 2026 → Jul 2027 expected | colon carcinoma | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| Phase 2 | NCT04707183 Comparator | May 2025 → May 2026 | — | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT06936410 Comparator | Mar 2025 → Mar 2026 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT07202624 Comparator | Feb → Jun 2025 | pharyngitis | Prince Sultan Military Medical City | Completed | No outcome recorded |
| Phase 2 | NCT06806202 Comparator | Dec 2024 → Mar 2025 overdue | — | Armed Forces Institute of Dentistry, Pakistan | Recruiting | No outcome recorded |
| Phase 2 | NCT06595017 Comparator | Oct 2024 → Sep 2025 overdue | myofascial pain syndrome | Misr University for Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06057675 Background | Mar 2024 → Jun 2026 overdue | skin cancer | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04880707 Comparator | Mar 2024 → Aug 2026 overdue | — | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT04614610 Comparator | Jan 2024 → Jan 2025 | sickle cell disease | Community Medical Center, Toms River, NJ | Unknown | No outcome recorded |
| Phase 2 | NCT05800834 Comparator | Sep 2023 → Mar 2024 | breast cancer, head and neck cancer | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05692167 Comparator | Jul → Oct 2023 | cataract | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT05378113 Comparator | May → Aug 2023 | — | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT05866653 Comparator | Mar → Jul 2023 | chemotherapy-induced neuropathy | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT05707208 Comparator | Mar 2023 → Dec 2025 | chronic pain syndrome | Sustained Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06040034 Comparator | Feb → May 2023 | — | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT05653401 Comparator | Nov 2022 → Aug 2023 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT04427904 Comparator | Jun 2022 → Dec 2024 | thyroid gland disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 2 | NCT05340231 Background | May → Dec 2022 | colorectal cancer | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT05348200 Comparator | Apr 2022 → Apr 2023 | hemorrhoid | Citius Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04995497 Comparator | Aug 2021 → Apr 2023 | chronic pain syndrome | Archit Sharma | Completed | No outcome recorded |
| Phase 2 | NCT05134181 Comparator | Aug 2021 → Aug 2022 | arthritis, sacroiliac | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT04724759 Background | Jun 2021 → Apr 2023 | temporomandibular joint disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04732507 Background | Apr 2021 → Dec 2026 expected | myofascial pain syndrome | University of Arizona | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT04817982 Comparator | Apr → May 2021 | — | Zealand University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05044468 Comparator | Mar 2021 → May 2026 overdue | pleural neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04634656 Comparator | Jan → Nov 2021 | cognitive disorder | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03787147 Background | Nov → Dec 2020 | — | Albert Einstein College of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT05414305 Background | Oct 2020 → Dec 2023 | interstitial cystitis | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04401176 Comparator | Sep 2020 → Jun 2023 | interstitial cystitis | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04207411 Comparator | Aug 2020 → Oct 2022 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT04449289 Comparator | Jul 2020 → Dec 2021 | malignant pancreatic neoplasm | Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor | Unknown | No outcome recorded |
| Phase 2 | NCT04260685 Comparator | Feb → Jun 2020 | lumbar disk disease | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT05112354 Background | Dec 2019 → Jun 2021 | sudden sensorineural hearing loss | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03844412 Comparator | Nov 2019 → Mar 2024 | endometriosis, fibromyalgia, interstitial cystitis, irritable bowel syndrome +4 | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04031131 Comparator | Oct 2019 → Jan 2020 | hemorrhoid | Julie Dawson | Completed | No outcome recorded |
| Phase 2 | NCT03885596 Background | Mar → Jul 2019 | — | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03908944 Background | Jan 2019 → Jan 2021 | — | Steven Edelstein | Withdrawn | No outcome recorded |
| Phase 2 | NCT03663101 Background | Oct 2018 → Nov 2019 | chronic pain syndrome | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT04062357 Comparator | Apr 2018 → Jan 2019 | — | Sohag University | Completed | No outcome recorded |
| Phase 2 | NCT03238625 Comparator | Aug → Oct 2017 | — | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT03240783 Background | Jul → Dec 2017 | sciatica | St George Hospital, Australia | Unknown | No outcome recorded |
| Phase 2 | NCT03119181 Comparator | Apr → May 2017 | — | Tusker Medical | Completed | No outcome recorded |
| Phase 2 | NCT02870738 Comparator | Apr 2017 → Feb 2026 overdue | interstitial cystitis | Corewell Health East | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03047070 Comparator | Feb 2017 → Dec 2021 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03072381 Comparator | Jan 2017 → Oct 2020 | tendinosis | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT03262857 Background | Sep 2016 → Sep 2018 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02839668 Comparator | Aug 2016 → Sep 2019 | breast cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2 | NCT03199924 Comparator | Jul 2016 → Jan 2022 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT03134612 Comparator | Jul → Sep 2016 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2 | NCT02710305 Comparator | Apr → Nov 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02732093 Comparator | Apr → Jul 2016 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02718976 Background | Mar → Apr 2016 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT03034382 Background | Jan 2016 → May 2017 | rotator cuff syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02658773 Comparator | Jan → May 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02597257 Comparator | Aug 2015 → Jul 2016 | diabetic polyneuropathy, postherpetic neuralgia | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03030560 Comparator | Apr 2015 → Aug 2016 | — | Abdelrady S Ibrahim, MD | Completed | No outcome recorded |
| Phase 2 | NCT02270255 Comparator | Apr 2015 → Nov 2017 | leiomyoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2 | NCT02332057 Comparator | Feb → Sep 2015 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT02253966 Comparator | Oct 2014 → Mar 2016 | osteoarthritis, knee | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02252926 Background | Sep 2014 → Dec 2015 | mucositis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02066844 Background | Feb → Aug 2014 | osteoarthritis, hip | Cartiva, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02044991 Comparator | Oct 2013 → Feb 2017 | — | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT01930877 Comparator | Aug 2013 → Apr 2014 | — | Baylor College of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT02733757 Background | May 2013 → Oct 2015 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 2 | NCT01878864 Comparator | Nov 2012 → Jun 2013 | periodontitis | Ove Andersen | Terminated | No outcome recorded |
| Phase 2 | NCT01794533 Comparator | Oct 2012 → Jan 2013 | pulpitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT01571791 Comparator | Jun 2012 → Dec 2021 | heart valve disorder | Mansoura University | Suspended | No outcome recorded |
| Phase 2 | NCT00701233 Background | Jun 2012 → Oct 2018 | carpal tunnel syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT01589432 Comparator | Apr → Nov 2012 | diabetic polyneuropathy | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01897259 Background | Mar 2012 → Jun 2019 | epicondylitis | Christine M. Kleinert Institute for Hand and Microsurgery | Unknown | No outcome recorded |
| Phase 2 | NCT01832675 Comparator | Mar → Aug 2012 | — | Ove Andersen | Completed | No outcome recorded |
| Phase 2 | NCT01262560 Comparator | Feb 2012 → Feb 2014 | esophagitis, lung neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01939743 Background | Oct 2011 → Sep 2012 | prostate carcinoma | Aga Khan University | Completed | No outcome recorded |
| Phase 2 | NCT01394250 Comparator | Jun 2011 → Sep 2013 | anxiety | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT01155986 Comparator | Aug 2010 → Nov 2012 | chronic pain syndrome, neuropathy, painful | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT01572116 Comparator | Jan 2010 → Jun 2011 | pulpitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT00975910 Comparator | Sep 2009 → May 2012 | — | Capital Medical University | Completed | No outcome recorded |
| Phase 2 | NCT01205477 Background | Sep 2009 → Jul 2010 | bursitis | Autonomous University of Nuevo León | Completed | No outcome recorded |
| Phase 2 | NCT00916942 Background | Jun 2009 | postherpetic neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2 | NCT01106716 Comparator | Mar 2009 → Mar 2010 | postherpetic neuralgia | KAI Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00907829 Comparator | Feb 2009 → Jan 2013 | stroke disorder | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
| Phase 2 | NCT01620112 Comparator | Feb 2009 → Jul 2011 | — | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 2 | NCT01302483 Comparator | Dec 2008 → Jan 2009 | — | St. Renatus, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00597766 Background | Dec 2007 → Feb 2012 | arthropathy | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00651313 Comparator | Aug 2007 → Jun 2008 | dysmenorrhea | Juniper Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00483717 Background | Jul 2007 → Jan 2008 | migraine disorder | Egalet Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00904618 Background | Jan 2007 → Mar 2009 | female stress incontinence | University of Sherbrooke | Completed | No outcome recorded |
| Phase 2/339 trials | ||||||
| Phase 2/3 | NCT07150481 Comparator | Oct 2025 → Dec 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07000058 Comparator | Jun → Dec 2025 overdue | — | Misr University for Science and Technology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT07062497 Background | Jan → Dec 2025 overdue | abdominal wall malformation | Federal University of Rio de Janeiro | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06427707 Comparator | Jun → Oct 2024 overdue | esophageal varices with bleeding | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06266481 Comparator | Mar → Apr 2024 | — | Pharos University in Alexandria | Unknown | No outcome recorded |
| Phase 2/3 | NCT05786378 Background | Jun 2023 → Jan 2024 | sensorineural hearing loss disorder, sudden hearing loss disorder | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05367271 Background | Aug 2022 → Sep 2024 | plantar fasciitis | Western Institute for Veterans Research | Completed | No outcome recorded |
| Phase 2/3 | NCT05313256 Comparator | Jul 2022 → Jul 2024 | obstetric disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2/3 | NCT04650074 Comparator | Nov 2021 → Jan 2024 | complex regional pain syndrome type 1, neuropathy, painful | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2/3 | NCT04887818 Background | Jun → Dec 2021 | ulcer of anus and rectum | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT04733781 Comparator | Feb → Jun 2021 | musculoskeletal system disorder, snakebite envenomation | Jeffrey Alan Klein, MD | Unknown | No outcome recorded |
| Phase 2/3 | NCT04523961 Comparator | Jan 2021 → Feb 2025 | local anesthetic poisoning | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT04356352 Comparator | Sep 2020 → Aug 2023 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT04276298 Comparator | Sep 2020 → Feb 2022 | hemorrhoid | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 2/3 | NCT04393610 Comparator | May → Aug 2020 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04201249 Comparator | Dec 2019 → Dec 2021 | epicondylitis | Hospital de Santa Maria, Portugal | Unknown | No outcome recorded |
| Phase 2/3 | NCT03843879 Comparator | Apr 2019 → Mar 2021 | — | Benaroya Research Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03730714 Comparator | Nov 2018 → Aug 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03382743 Comparator | Dec 2017 → Mar 2018 | uterine disorder | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03363425 Comparator | Nov 2017 → Nov 2018 | leiomyoma | University of Athens | Unknown | No outcome recorded |
| Phase 2/3 | NCT03005171 Comparator | Jan → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02870673 Comparator | Aug 2016 → Aug 2017 | carpal tunnel syndrome | Taipei Medical University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02503904 Comparator | Oct 2015 → Jun 2019 | venous thromboembolism | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 2/3 | NCT01145326 Comparator | Jan 2015 → Dec 2017 | — | University of Oklahoma | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02452112 Comparator | Nov 2014 → Dec 2015 | postherpetic neuralgia | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT02061475 Comparator | Apr 2014 → Mar 2015 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02935972 Comparator | Nov 2013 → Nov 2014 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02707081 Comparator | Jun 2013 → Dec 2015 | — | Benha University | Completed | No outcome recorded |
| Phase 2/3 | NCT02487914 Comparator | Jan 2013 → Mar 2014 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01837446 Comparator | Jul 2011 → Jul 2012 | stomatitis | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01659359 Background | Jan 2011 → Jul 2012 | anxiety | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00932542 Comparator | Apr 2010 → Feb 2011 | hemorrhoid | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2/3 | NCT00806871 Comparator | Nov 2008 → Apr 2012 | carpal tunnel syndrome | Region Skane | Completed | No outcome recorded |
| Phase 2/3 | NCT00617097 Comparator | Jan 2008 → May 2009 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00556478 Comparator | Oct 2007 → Oct 2009 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT00674622 Background | Sep 2007 → Oct 2010 | epicondylitis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2/3 | NCT00835939 Comparator | Sep 2007 → Jan 2010 | enthesopathy, tendinosis | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT01279551 Comparator | Jan 2004 → Sep 2010 | — | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3106 trials | ||||||
| Phase 3 | NCT07672236 Comparator | Jul → Dec 2026 expected | head and neck cancer, mucositis | OncoZenge AB | Recruiting | No outcome recorded |
| Phase 3 | NCT07592143 Background | Jul → Dec 2026 expected | — | King Edward Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04990128 Comparator | Jun 2026 → Jul 2027 expected | osteoarthritis, hip | The Cleveland Clinic | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07650396 Comparator | Jun 2026 → Dec 2027 expected | disease of the tendon | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05279937 Comparator | Jun 2026 → Jun 2027 expected | Ehlers-Danlos syndrome | Tulane University | Not yet recruiting | No outcome recorded |
| Show all 106 trials opens the full record — a long page | ||||||
| Phase 4319 trials | ||||||
| Phase 4 | NCT07273006 Comparator | Sep 2026 → Nov 2028 expected | arthropathy | Universidad Complutense de Madrid | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644923 Background | Aug 2026 → Aug 2028 expected | — | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06792474 Comparator | Aug 2026 → Aug 2027 expected | vertebral column disorder | Dartmouth-Hitchcock Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07430085 Comparator | Jul 2026 → Jan 2028 expected | osteoarthritis, knee | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07224711 Comparator | Jul 2026 → May 2028 expected | — | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Show all 319 trials opens the full record — a long page | ||||||
| Phase not applicable429 trials | ||||||
| — | NCT07624890 Comparator | Dec 2026 expected | neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Not yet recruiting | No outcome recorded |
| — | NCT07509918 Comparator | Sep → Oct 2026 expected | — | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07630155 Background | Aug 2026 → Aug 2027 expected | renal pelvis/ureter urothelial carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| — | NCT07665463 Background | Jul → Dec 2026 expected | — | Jagiellonian University | Not yet recruiting | No outcome recorded |
| — | NCT07687290 Comparator | Jun → Dec 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Show all 429 trials opens the full record — a long page | ||||||
Evidence & citations 114 cited values
Every value below carries the sentence it was read from. 2,011 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lidocaine | “The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over...” NCT03112720 ↗1803“A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in...” NCT01506154 ↗ “Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the...” NCT06029049 ↗ “Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of...” NCT03072381 ↗ “all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone®...” NCT02930057 ↗ “Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus...” NCT06456099 ↗ “Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon...” NCT05648032 ↗ “General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and...” NCT07665463 ↗ “ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗ “Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the...” NCT04557943 ↗ “Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus...” NCT03463915 ↗ “Patients in the Lidocaine group received 3 mL of 2% lidocaine, diluted with 7 mL of normal saline to prepare a 10 mL solution, which was administered intravenously as a stat...” NCT07248384 ↗ “Patients in the Lidocaine group received 3 mL of 2% lidocaine, diluted with 7 mL of normal saline to prepare a 10 mL solution, which was administered intravenously as a stat...” NCT07248332 ↗ “EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately...” NCT00444626 ↗ “Comparison of the Effects of Intravenous Administration of Dexmedetomidine 0.5 μg/kg Body Weight With Intravenous Lidocaine 1.5 mg/kg Body Weight on Blood Pressure and Heart...” NCT06573957 ↗ “the intervention group (BRA-CLO) will receive bilateral RSB with a solution containing 8 mL of lidocaine 2%, 8 mL of ropivacaine 1%, and clonidine 75 mcg, diluted in 0.9%...” NCT07062497 ↗ “Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to...” NCT06068166 ↗ “This study will compare the effects of remifentanil (bolus dose of 0.25 mcg/kg or 0.5 mcg/kg) to lidocaine (bolus dose of 1mg/kg) when given prior to emergence to prevent...” NCT01026129 ↗ “1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine...” NCT05738564 ↗ “Group I patients received cervical epidural injections with lidocaine 0.5% preservative-free, 5 mL, whereas Group II patients received 0.5% preservative-free lidocaine mixed...” PMID 24077193 ↗ Sep 2013 “heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be...” NCT02870738 ↗ “This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar...” NCT06806202 ↗ “The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗ “LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and...” NCT01879683 ↗ “The EMLA group received EMLA cream which consisted of 2.5% lidocaine and 2.5 % prilocaine in 2 ml of water/oil emulsion and then they received tegaderm as the dressing for...” NCT03134391 ↗ “2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound...” NCT05339542 ↗ “An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group...” NCT04941118 ↗ “EMLA®, a topical anesthetic cream containing lidocaine and prilocaine, will be applied under occlusion prior to tape application during 30 minutes with the aim of anesthetize...” NCT07034456 ↗ “liposome-encapsulated 2% ropivacaine, liposome-encapsulated 1% ropivacaine, a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (EMLA), and liposomal placebo gel,...” PMID 21106282 ↗ Nov 2010 “LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the...” NCT02395042 ↗ “For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml...” NCT05260125 ↗ “Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the...” NCT01994759 ↗ “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗ “On the other hand, a recent study showed the interest of administering lidocaine 2% by J-tip, a needle-free injection technique not available in France, before infiltration of...” NCT05032508 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium,...” NCT05485480 ↗ “A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total...” NCT07084753 ↗ “Antoniades et al. demonstrated that topical lidocaine through the bronchoscope significantly decreased cough frequency and the total dose of sedation required during flexible...” NCT03109392 ↗ “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ “Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of...” NCT04247230 ↗ “a standard Tuohy block needle will be advanced through a skin wheal of lidocaine until its tip is in the hypoechoic area immediately distal saphenous nerve adjacent to the...” NCT06784882 ↗ “One ml Lidocaine (10%) will be injected at the end of therapy since irritation of nerve fibers by the electrical field (without thermolesion) has been described as occurring frequently.” NCT04737993 ↗ “After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.” NCT02517437 ↗ “after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle.” NCT03131466 ↗ “1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.” NCT05984121 ↗ “Participants will be given three sprays of 10% Lidocaine (Lidocaine 10% pump spray, Egis) 3 minutes before the interventionist performed the insertion of a catheter into their vein” NCT07212192 ↗ “The purpose of this study is to compare the effects of vapocoolant spray and topical lidocaine 2.5% + prilocaine 2.5% cream (EMLA) on reducing pain during needle electromyography.” NCT01606046 ↗ “20 mL of local anesthetic solution (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected bilaterally into the erector spinae plane at the T7-T8 level before incision.” NCT07057934 ↗ “The selected patients will receive transforaminal epidural injection of premixed steroids with local anesthetic in a total volume 2 ml (7 mg Betamethasone and 20 mg Lidocaine 2%)” NCT05288920 ↗ “1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.” NCT07120204 ↗ “Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.” NCT00904020 ↗ “tumescent formulation of cefazolin (1gm) and metronidazole (500mg/100ml) in a dilute solution of lidocaine (1gm), epinephrine (1mg) in 100ml and sodium bicarbonate (10mEq/10ml)” NCT03226626 ↗ “Before intubation of the trachea, a lidocaine 1 mg / kg bolus was added intravenously, with the simultaneous establishment of a continuous infusion at a dose of 1.5-2 mg/kg/h.” NCT05514652 ↗ “EMLA cream 5% 25g lidocaine, 25g prilocaine; Astra Zeneca. Topically applied followed by Tegaderm dressing to cover. Length of duration monitored and recorded as part of study” NCT06274905 ↗ “A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.” NCT07105540 ↗ “Lidocaine (Xylocaine) has a better pharmacokinetic and pharmacodynamics profile than levobupivacaine and is also widely used as local anaesthetic agent in clinical practice.” NCT04397484 ↗ “Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution.” NCT06545812 ↗ “general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.” NCT03569046 ↗ “10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance” NCT01995461 ↗ “will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.” NCT01552096 ↗ “5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon.” NCT01123889 ↗ “EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.” NCT03313336 ↗ “All analgesic procedures such as lidocaine, paracetamol, ultracaine, and paracervical block with ultracaine can be used for reducing pain score in postoperative period.” PMID 24455735 ↗ Dec 2013 “Participants who take part in this study, may receive 6cc of 2% lidocaine gel or 6cc of a non-medicated gel in the vagina before a paracervical block for IUD placement.” NCT06974032 ↗ “Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation” NCT02016976 ↗ “receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s” NCT04414917 ↗ “Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.” NCT03417193 ↗ “Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 2% Lidocaine 1:100,000 epinephrine following endodontic treatment.” NCT05338671 ↗ “The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS.” NCT04901065 ↗ “Supracapsular nerve block: injection of 10 mL of 1% lidocaine (2 mL along the needle path and 8 mL around the nerve), followed by an injection of 1 mL of DIPROSTENE®.” NCT07680504 ↗ “steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.” NCT03101033 ↗ “Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation.” NCT06088875 ↗ “Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space.” NCT01934868 ↗ “a combination topical anesthetic, consisting of 20% lidocaine, 4% tetracaine and 2% phenylephrine (TAC Alternate Gel, Compounding Arts Pharmacy, Lafayette, LA).” NCT00846690 ↗ “The study drug, EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule, is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine.” NCT05361369 ↗ “To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine.” NCT05291650 ↗ “Group l include 50 patients who will be injected with one intra\_articular injection of 2 ml of methylprednisolone acetate 40 mg/ml mixed with 2ml of lidocaine” NCT05742061 ↗ “EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)” NCT06056947 ↗ “1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia” NCT05367271 ↗ “Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance.” NCT05567315 ↗ “The administered dose will include 0.2% lidocaine combined with 0.2% ropivacaine, at a dose of 0.4 ml/kg per side, without exceeding toxic dose limits per kg.” NCT07139691 ↗ “The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine.” NCT03138577 ↗ “Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio.” NCT06617065 ↗ “The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml).” NCT03818126 ↗ “PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis.” NCT03578783 ↗ “Intravenous lidocaine (IVL), an alternative to epidural analgesia (EA) for laparotomies, has demonstrated anti-inflammatory and anti-hyperalgesic effects.” PMID 41790838 ↗ Mar 2026 “For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.” NCT05178849 ↗ “will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.” NCT05134181 ↗ “Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.” NCT06133712 ↗ “The 5 cc BMAC dose or 1 cc triamcinolone of 40 mg with 4 cc of lidocaine 1% will be injected into a single affected hip joint under ultrasound guidance.” NCT04990128 ↗ “Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound” NCT02246530 ↗ “A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.” NCT03908944 ↗ “a total of 4 mL of local anesthetic solution consisting of 2 mL of 0.5% bupivacaine and 2 mL of 2% lidocaine (Aritmal) will be injected on each side.” NCT07608861 ↗ “Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)” NCT04281017 ↗ “Local anesthesia (e.g., 2% Lidocaine) and conscious sedation (e.g., Fentanyl and Midazolam) will be administered to the patient during the procedure” NCT06426992 ↗ “The diagnostic injectate will be a local anesthetic without corticosteroid (1% lidocaine) with low volumes of 0.5 ml per branch to limit diffusion.” NCT07273006 ↗ “mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day.” NCT02577393 ↗ “This research study uses Eutectic Mixture of Local Anesthetics (EMLA) Cream (lidocaine 2.5% and prilocaine 2.5%) as the topical anaesthetic agent.” NCT05078463 ↗ “Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment.” NCT02401074 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back” NCT00904397 ↗ “Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)” NCT00904111 ↗ “Single intra-articular injection of dexamethasone 4 mg (0.5 mL) combined with lidocaine 2% (0.5 mL), total 1 mL, into the superior joint space.” NCT07691684 ↗ “The VASAUC was significantly smaller after oral rinse with 0.05 mol/L GABA, 0.5 mol/L GABA, and 1% lidocaine than after oral rinse with water.” PMID 29024230 ↗ Oct 2017 “1 mL of 2% lidocaine with epinephrine was delivered via buccal infiltration using a conventional aspirating syringe and 27-gauge short needle.” NCT06992193 ↗ “one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride.” NCT03282045 ↗ “Comparing the two versions (the room temperature and + 4°C) of the gold standard of local anesthetics, the solution, which contains lidocaine.” NCT07198022 ↗ “hydrogels containing LAs - lidocaine and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA and placebo hydrogel” NCT05912335 ↗ “Products containing lidocaine are used in everyday practice, sometimes combined with vasoconstrictors such as oxymetazoline or phenylephrine.” NCT04583137 ↗ “Multiprofen-CC™ is a multimodal topical cream including ingredients ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%).” NCT06202989 ↗ “Lumbar Transforaminal Epidural Steroid Injections was administered, consisting of 4 mg dexamethasone and 0.33% lidocaine in a 3 ml solution” NCT06656429 ↗ “Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.” NCT03288259 ↗ “Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)” NCT06301503 ↗ “with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.” NCT02669303 ↗ “intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance” NCT03742466 ↗ “Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance” NCT05450913 ↗ “This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w).” NCT02301052 ↗ “Intervention group will receive 30 ml of a 50/50 mixture of isobaric bupivacaine 0.5% and lidocaine 1%, containing 8 mg of dexamethasone.” NCT07313553 ↗ “combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids” NCT04010266 ↗ “LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.” NCT05461053 ↗ “The dental local anesthetic (2% lidocaine with 1:100,000 epinephrine) will be delivered as the Temporo-masseteric Nerve Block injection.” NCT07094542 ↗ “single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)” NCT02334475 ↗ “20cc of 2% lidocaine with 1:200,000 epinephrine + 20 cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve” NCT02280291 ↗ “Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1.” NCT02411110 ↗ “10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.” NCT01832675 ↗ “As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine” NCT03175913 ↗ “This arm will receive a Triple Mixture oral rinse (combination of 0.19% w/w Lidocaine, 0.29% w/w Nystatin, and 5.50% w/v Hydroxides).” NCT06875791 ↗ “Lidocaine (Xylocaine), also called lignocaine, is a potent local anesthetic agent, widely used both topical and injection anesthesia.” NCT03265197 ↗ “Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block” NCT05692167 ↗ “These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine” NCT03543033 ↗ “Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate” NCT03124680 ↗ “The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site.” NCT05980572 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)” NCT00904605 ↗ “Intra-articular injection consisting of 80 mg of methylprednisolone acetate, 2 mL of lidocaine (1%), and 4 mL of ropivacaine (0.5%)” NCT07497737 ↗ “administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side” NCT06155097 ↗ “LiRIS contains Lidocaine, a marketed drug (approved by Health Canada) which is commonly used for local (skin or oral)anaesthesia.” NCT01150565 ↗ “3mL lidocaine (without epinephrine) 1% solution combined with 1mL triamcinolone acetonide injectable solution, USP (40mg per mL)” NCT07544576 ↗ “Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)” NCT01606969 ↗ “For local anesthesia, 1 mL of 1% lidocaine will be injected with a 25 gauge 2-inch needle into the skin and subcutaneous tissues” NCT07278323 ↗ “Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)” NCT01845532 ↗ “This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine” NCT02044991 ↗ “A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site.” NCT04275336 ↗ “Intravesical Alkalized Lidocaine for the Treatment of Overactive Bladder (OAB), a Randomized, Double-blinded Controlled Trial” NCT00427648 ↗ “Experimental - A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.” NCT03199417 ↗ “Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain” NCT00904202 ↗ “Standard care includes intravesical instilled 1-2% lidocaine with a dwell time of at least 15 minutes before the procedure.” NCT07387315 ↗ “EMLA anesthetic ointment (AO-Astra Zeneca) is an emulsion of lidocaine 2.5% and prilocaine 2.5% in a ratio of 1:1 by weight” NCT03501212 ↗ “Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.” NCT02246179 ↗ “These studies have shown fentanyl and lidocaine to be effective in reducing the incidence of pain on rocuronium injection.” PMID 18008122 ↗ Nov 2007 “The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ “The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline.” NCT05086926 ↗ “The low pH causes burning pain when applied, that is why it is coadministered with lidocaine to reduce pain of injection.” NCT01651988 ↗ “50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden)” NCT00959595 ↗ “30ml total volume of 0.25 plain bupivacaine 1.5mg/kg with lidocaine 1% 3mg/kg with 8mg dexamethasone in group A patients” NCT06131593 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).” NCT03197558 ↗ “Postoperative topical lidocaine and PCA (piritramide 0.5 mg/ml; infusion 0.5 mg/h, bolus 1.5 mg, lock out 20 minutes)” NCT05831761 ↗ “injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection” NCT02054767 ↗ “Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.” NCT05747469 ↗ “The investigator will add Sodium bicarbonate in lidocaine with adrenaline (1:80,000 ) for Buffered Local anesthesia.” NCT07592143 ↗ “Ultrasound-guided injection of 1 ml lidocaine combined with 1 ml betamethasone administered at the A1 pulley level” NCT07681804 ↗ “The study group (OFA group) will receive a combination of clonidine, magnesium sulfate, ketamine, and lidocaine.” PMID 34838109 ↗ Nov 2021 “preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine” NCT01513564 ↗ “1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control” NCT06345833 ↗ “with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline” NCT05291364 ↗ “Topical 5% lidocaine medicated plaster treatment was administered by patients to the area of most painful skin.” PMID 19301937 ↗ 2009 “Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.” NCT04858360 ↗ “Lidocaine spray as a local anaesthetic agent was applied to the cervix before intrauterine device application.” NCT07155785 ↗ “A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered.” NCT07043179 ↗ “A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered.” NCT07042282 ↗ “Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally.” NCT04148729 ↗ “Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash” NCT03490396 ↗ “lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly” NCT05577962 ↗ “Targeted topical analgesics such as 5% lidocaine patches have been known to improve acute and chronic pain.” PMID 36089597 ↗ Sep 2022 “An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.” NCT03363789 ↗ “After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region.” NCT03279757 ↗ “Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.” NCT01238536 ↗ “The standard protocol used a pre-procedure instillation of 50 ml of 1% lidocaine and 50 ml of 0.9% saline.” PMID 40025238 ↗ Mar 2025 “In addition, 40 mg of Lidocaine were added, this aimed to reduce the pain on injection caused by Propofol.” NCT04285528 ↗ “Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors” NCT05484687 ↗ “An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions” NCT02752477 ↗ “The intraperitoneal administration of lidocaine solution (total dose, 3.5 mg/kg) will be done as follows” NCT03693820 ↗ “The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design.” NCT05035810 ↗ “Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site” NCT01115062 ↗ “rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.” NCT04500249 ↗ “A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia” NCT05112354 ↗ “peribulber injection of lidocaine 2٪ (4 ml) + Cisatracurium (0.5 mg in 0.5 ml) + Normal Saline (0.5 ml).” NCT07519694 ↗ “an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves” NCT06347874 ↗ “2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure” NCT06769204 ↗ “10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.” NCT01737437 ↗ “solution containing sterile, cooled 0.9% sodium chloride and 1% lidocaine with epinephrine (1:100,000)” NCT06820164 ↗ “will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted.” NCT06683924 ↗ “Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.” NCT06907277 ↗ “General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg” NCT06892600 ↗ “Steroid injection , Triamcinolone acetonide(40mg/ml) 1 ml + 1%Lidocaine without adrenaline 3 ml = 4ml” NCT06453603 ↗ “The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation.” NCT06490718 ↗ “The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.” NCT04709484 ↗ “local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes” NCT05786378 ↗ “one cream will be an anesthetic (lidocaine and prilocaine) and the other will be a placebo lotion.” NCT01324843 ↗ “A skin wheal will be made by 1 ml of lidocaine HCl 2% at L3-4 interspace using a 25-gauge needle.” NCT07564180 ↗ “2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use.” NCT04880707 ↗ “It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar).” NCT05887258 ↗ “For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.” NCT04395417 ↗ “A placebo patch and a lidocaine patch will then be applied to the volar aspect of each forearm.” NCT00373893 ↗ “OFA (n=159) consisting of intravenous ketamine, dexamethasone, lidocaine, and magnesium sulfate” PMID 42190101 ↗ May 2026 “lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h” NCT07116564 ↗ “The Effectiveness of Mesotherapy (Lidocaine and Proxicam) in the Treatment of Chronic Migraine” NCT06118190 ↗ “after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.” NCT05445921 ↗ “Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation” NCT02224170 ↗ “For Lido-IV group, patients received a loading dose of Lidocaine than a continuous infusion.” NCT06383845 ↗ “The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.” NCT02300727 ↗ “Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1” NCT04588389 ↗ “Lidocaine spray 10 % (Xylocaine 10% pump spray; AstraZeneca BV, Zoetermeer, The Netherlands)” NCT06354816 ↗ “after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle” NCT03746418 ↗ “10 mL of 1% lidocaine with epinephrine combined with 10 mL of 0.5% bupivacaine hydrochloride” PMID 42100467 ↗ Apr 2026 “using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)” NCT06176404 ↗ “Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml” NCT05464862 ↗ “under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine” NCT02702206 ↗ “Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation” NCT05405049 ↗ “Topical anaesthesia with lidocaine will be provided through nebulisation and instillation.” NCT03546088 ↗ “Group L received TPI with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline” NCT02293083 ↗ “LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.” NCT01824303 ↗ “The -Mulimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine” NCT07568938 ↗ “lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.” NCT00805298 ↗ “The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine” NCT05752799 ↗ “Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent.” NCT04787731 ↗ “Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.” NCT05653401 ↗ “using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine” NCT05335070 ↗ “Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used.” NCT05076903 ↗ “The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000” NCT02355678 ↗ “In addition, Lidocaine will be added to reduce the pain on injection caused by Propofol.” NCT04473846 ↗ “Lidocaine hydrochloride 20 mg/mL, solution, 20 mL ampoule for intravenous administration” NCT07274254 ↗ “lubricant gel with lidocaine will be administered to all patients just before cystoscopy” NCT03831321 ↗ “Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint” NCT04568993 ↗ “Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base” NCT06030297 ↗ “Group I received 10 mL caudal epidural injections of local anesthetic, lidocaine 0.5%;” PMID 22828681 ↗ Jul 2012 “Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group” NCT04916353 ↗ “topical anaesthetic gel (containing lidocaine active ingredient) administered rectally” NCT04031131 ↗ “Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)” NCT05340231 ↗ “Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection” NCT05027516 ↗ “Subsequently, 1 mL of 5% injectable lidocaine is administered into each nasal cavity.” NCT07354464 ↗ “2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control” NCT03243032 ↗ “Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.” NCT06974617 ↗ “a eutectic mixture containing 25 mg/g of lidocaine and 25 mg/g of prilocaine (EMLA®)” NCT01860235 ↗ “Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:” NCT04355468 ↗ “Propofol 2mg/kg plus lidocaine 1mg/kg over 10 min and 10 min before end of surgery.” NCT07601698 ↗ “Lidocaine was injected on 16 patients' three trigger point in the masseter muscle.” NCT05228327 ↗ “Octocaine® (1.8mL/cartridge contains 20mg/mL Lidocaine + 1:100,000 epinephrine)” NCT05804630 ↗ “A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);” NCT01262560 ↗ “Instead of a regional block, an intravenous infusion of lidocaine will be used.” NCT06793527 ↗ “Lidocaine 2% will be mixed with bupivacaine to expedite the onset of analgesia.” NCT03730714 ↗ “1% lidocaine with 1:100,000 epinephrine injected directly into operative site.” NCT03135340 ↗ “40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel” NCT00701233 ↗ “An inferior alveolar nerve block was given with 2% lidocaine with epinephrine” NCT05239078 ↗ “Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.” NCT05348200 ↗ “Commercially available Lidoderm (lidocaine patch 5%) was provided to patients” NCT00904540 ↗ “Patients in both study groups will receive 1 mg/kg of lidocaine intravenously” NCT05509192 ↗ “All patients received 8 mg dexamethasone and lidocaine at a dose of 1 mg/kg.” NCT06958913 ↗ “Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml” NCT05834023 ↗ “then mixed with 1 mL Lidocaine 2% for a total of 3mL volume in one syringe.” NCT05589285 ↗ “EMLA cream (lidocaine 2.5% and prilocaine 2.5% in a ratio of 1:1 by weight)” NCT03072394 ↗ “intravenous lidocaine for systemic analgesic and anti-inflammatory effects” NCT07310524 ↗ “20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection” NCT02379221 ↗ “Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)” NCT05970354 ↗ “70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours” NCT01654302 ↗ “Intradermal lidocaine will be used at the site of the needle insertion.” NCT02462681 ↗ “2% lidocaine injection treatment will be applied to the control group.” NCT05239091 ↗ “The new formulation ST-01 is a sustained release lidocaine formulation” NCT05193227 ↗ “Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine” NCT04253457 ↗ “Infiltration of lidocaine 1% with 1:100,000 epinephrine (maximum 10cc)” NCT05300685 ↗ “Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)” NCT02371759 ↗ “Both groups will receive lidocaine as the anesthesia for bronchoscopy” NCT02372760 ↗ “Local skin infiltration with 1-2 mL of 1% lidocaine at puncture site.” NCT07512219 ↗ “Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer” NCT03386552 ↗ “the drug mix included lidocaine, bupivacaine and water for injection” NCT02245126 ↗ “40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml.” NCT01109446 ↗ “Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.” NCT05937282 ↗ “Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg” NCT04108546 ↗ “regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)” NCT03453151 ↗ “Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used” NCT06092541 ↗ “standard a standard combination of methylprednisolone and lidocaine” NCT07217405 ↗ “using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution” NCT04888858 ↗ “Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin” NCT05658874 ↗ “5ml lidocaine will be injected 10 minutes before RZL-012 treatment” NCT05476679 ↗ “Injection of 15% dextrose with lidocaine at the lateral epicondyle” NCT00674622 ↗ “lidocaine nebulizer (5 ml of lidocaine 2% with oxygen flow 8 l/m)” NCT06395727 ↗ “1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline” NCT00806871 ↗ “A 2% lidocaine without vasoconstrictor injection into the cervix” NCT03111342 ↗ “All patients received local anesthesia (3-5 ml of 2% Lidocaine).” NCT04985695 ↗ “patients will receive only topical anesthesia with 1% lidocaine” NCT01444976 ↗ “Before induction, a lidocaine bolus of 1.5 mg/kg will be given” NCT07213687 ↗ “The bladder was instilled with 40 ml of 1% lidocaine solution” NCT06250543 ↗ “antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).” NCT03299517 ↗ “6.5 ml of 2% lidocaine (Lidocaine HCL -Sunny Pharmaceutical)” NCT07205757 ↗ “Patients will receive Lidoderm topical 5% lidocaine patches.” NCT03120351 ↗ “application of 5% Lidocaine gel (APL, Sweden) on the gingiva” NCT02644811 ↗ “2 mL of a 50:50 mixture of 2% lidocaine and 0.5% bupivacaine” NCT01670825 ↗ “Topical gel containing lidocaine (2%) plus diclofenac (0.5%)” NCT02961855 ↗ “Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine” NCT03087604 ↗ “Lidocaine mixed with diprospan injected into tender points.” NCT06344403 ↗ “epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil” NCT02838056 ↗ “The patient's skin will be anesthetized with 2% lidocaine.” NCT03413163 ↗ “0.3 mL 2% lidocaine is infiltrated at the injection sites.” NCT02534012 ↗ “1 cc of 2% lidocaine into the origin of the plantar fascia” NCT01127672 ↗ “lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.)” NCT00686127 ↗ “Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.)” NCT00904462 ↗ “Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)” NCT04081545 ↗ “Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes” NCT04648540 ↗ “non-buffered LA, 2% lidocaine with epinephrine 1:100,000” NCT05757648 ↗ “They will also recieve anesthetic of 1 ml 1% lidocaine.” NCT01897259 ↗ “Lidocaine is a drug commonly used for local anesthesia.” NCT04519463 ↗ “Lidocaine 2% 2ml was injected into each genicular nerve” NCT05219084 ↗ “skin infiltration with 2 mL of 1% lidocaine will be done” NCT04425447 ↗ “Skin infiltration will be done using 3 ml lidocaine 2%” NCT06011746 ↗ “Multimodal IV analgesia of lidocaine, ketamine and MS” NCT06661746 ↗ “Patients using cervical lidocaine spray for analgesia” NCT06540599 ↗ “procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream)” NCT06425978 ↗ “40 mg triamcinolone with 1% lidocaine, total of 2 ml” NCT05234840 ↗ “5mls 1% lidocaine will be used for skin infiltration” NCT03737604 ↗ “mixed with 5cc's of 1% lidocaine without epinephrine” NCT01132677 ↗ “Lidocaine 0.33% and Cetylpyridinium Chloride 0.10%” NCT02931357 ↗ “Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn” NCT04894864 ↗ “4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml” NCT03105674 ↗ “combination of ropivacaine 0.5% and lidocaine 2%” NCT04180943 ↗ “500 mg Lidocaine (25 ml of standard 2% solution)” NCT06343753 ↗ “Lidocaine loading dose 1.5 mg/kg i.v. infusion.” NCT04941040 ↗ “after local analgesia with 3 mL of 1% lidocaine” NCT05775861 ↗ “2% lidocaine with epinephrine 1: 100000 1.8 mL” NCT03176446 ↗ “including daily topical lidocaine 5% ointment.” NCT03640624 ↗ “Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗ “Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine” NCT01807962 ↗ “Dexmedetomidine, Lidocaine, Propofol, Ketamine” NCT05172739 ↗ “lidocaine 1% and bupivacaine 0,5% 1:1 mixture” NCT03454789 ↗ “with 10 ml of local anaesthetic lidocaine 1%” NCT03781908 ↗ “two puff lidocaine sprays on cervical mucosa” PMID 26609031 ↗ Oct 2015 “lidocaine 25 mg/g + prilocaine 25 mg/g cream” NCT02548533 ↗ “2 mL lidocaine (10 mg/mL), total volume 5 mL” NCT07183436 ↗ “lidocaine 1.5-2mg/kg (intravenous bolus)” NCT04507165 ↗ “placebo injection (Lidocaine) in capsule” NCT00840229 ↗ “0.5 ml of 1% preservative-free lidocaine” NCT04544683 ↗ “Lidocaine 1% with 1:100,000 epinephrine” NCT00578214 ↗ “a 1% lidocaine paracervical nerve block” PMID 28885425 ↗ Oct 2017 “2% lidocaine with epinephrine (2.25 mL)” NCT04951128 ↗ “40 mL of bupivacaine/lidocaine mixture” NCT04336917 ↗ “Local anesthesia: 2 cc of 1% Lidocaine” NCT00583011 ↗ “3mL of Linisol 2% (60mg of lidocaine)” NCT05930236 ↗ “lidocaine / tetracaine 70/70 mg patch” NCT00765934 ↗ “A lidocaine topical anesthetic cream” NCT01708447 ↗ “2.5% prilocaine-2.5% lidocaine cream” NCT06891794 ↗ “Clonidine 1 µg/kg plus 2% lidocaine” NCT02733757 ↗ “1% lidocaine paracervical injection” NCT02447029 ↗ “2.5% Lidocaine and 2.5% Prilocaine” NCT05060913 ↗ “tioconazole, tinidazole, lidocaine” NCT03839875 ↗ “Lidocaine iv bolus dose of 1mg/kg” NCT06736496 ↗ “adjuvant lidocaine and fentanyl” NCT03263117 ↗ “Injection of 12 mL of lidocaine” NCT03356145 ↗ “Lidocaine: 1.1.5mg/Kg iv bolus” NCT07558226 ↗ “Experimental: Lidocaine group” NCT04922359 ↗ “Group T (Inhaled Lidocaine)” NCT06705595 ↗ “IV-lidocaine (60 - 100 mg)” NCT07211399 ↗ “Lidocaine with epinephrine” NCT05267938 ↗ “Lidocaine patch q 12 hours” NCT04129086 ↗ “1% lignocaine (lidocaine)” NCT07675304 ↗ “2% Lignocaine (lidocaine)” NCT02807298 ↗ “Dexmedetomidine+Lidocaine” NCT05439005 ↗ “Omeza® Lidocaine Lavage” NCT05921292 ↗ “lidocaine hydrochloride” NCT04880928 ↗ “0.5 mL of 1% lidocaine” NCT04515966 ↗ “Xylocaine (lidocaine)” NCT01298310 ↗ “2 mL of 2% lidocaine” NCT07355712 ↗ “LMX4 (Lidocaine 4%)” NCT01842373 ↗ “Lidocaine 5 mg/Kg.” NCT03319563 ↗ “Drug: Lidocaine” NCT04634656 ↗ “Drug: Lidocaine” NCT03914235 ↗ “Lidocaine HCl” NCT03885596 ↗ “2% lidocaine” NCT06186921 ↗ “Lidocaine” NCT07624890 ↗ |
| Known as | 1% Lidocaine | “1% Lidocaine” NCT02822196 ↗ |
| Known as | 2-(diethylamino)-N-(2.6-dimethylphenyl) acetamide | “Lidocaine (or 2-(diethylamino)-N-(2.6-dimethylphenyl) acetamide) is the main prototype of amino-amide local anesthetics.” NCT06431165 ↗ |
| Known as | 4% liposomal lidocaine (Brand name = LMX4) | “4% liposomal lidocaine (Brand name = LMX4)” NCT00676364 ↗ |
| Known as | 5% lidocaine-medicated plaster | “5% lidocaine-medicated plaster (LMP), which can block the Na+ channels on Aδ and C fibres” PMID 34341037 ↗ Aug 2021 |
| Known as | 5LP | “comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms” NCT02763592 ↗ |
| Known as | Akten | “The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%...” NCT01027611 ↗ |
| Known as | ALGRX 3268 | “ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗3“ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia within 3 minutes to provide painless needle or cathether insertion for blood drawing.” NCT00146185 ↗ |
| Known as | Alkalinized lidocaine | “Alkalinized lidocaine in the endotracheal tube (ETT) cuff decreases the incidence of cough and throat pain on emergence after surgery lasting more than 2 hours.” PMID 29189279 ↗ Feb 2018 |
| Known as | Anestol pomade(lidocaine) | “Anestol pomade(lidocaine)” NCT05125796 ↗ |
| Known as | Aritmal | “1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.” NCT07120204 ↗1“a total of 4 mL of local anesthetic solution consisting of 2 mL of 0.5% bupivacaine and 2 mL of 2% lidocaine (Aritmal) will be injected on each side.” NCT07608861 ↗ |
| Known as | AritmalR | “Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients.” NCT03189329 ↗ |
| Known as | Aspercreme | “Aspercreme (Lidocaine Patch 4%)” NCT05106400 ↗ |
| Known as | Autologous PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03026855 ↗ |
| Known as | Buffered Lidocaine | “1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm” NCT01759459 ↗3“Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)” NCT06661902 ↗ “Drug: Buffered Lidocaine” NCT06974019 ↗ |
| Known as | CNTX-2022 | “CNTX-2022 (lidocaine gel, 40%)” NCT02679339 ↗ |
| Known as | DEBOCAINE | “This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight...” NCT03362905 ↗2“The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical...” NCT03701984 ↗ “Local infiltration with Lidocaine HCL 1%'Debocaine'” NCT05850455 ↗ |
| Known as | depocaine | “5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to...” NCT02883179 ↗ |
| Known as | Diprophos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02916940 ↗ |
| Known as | Drug: lidocaine hydrochloride | “Drug: lidocaine hydrochloride” NCT00693043 ↗ |
| Known as | Esracaine | “Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes” NCT03210038 ↗ |
| Known as | Experimental Group 1 triamcinolone and lidocaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03127137 ↗ |
| Known as | Hospira brand 1% Lidocaine in 20 mL vial | “Hospira brand 1% Lidocaine in 20 mL vial” NCT01759459 ↗ |
| Known as | IV lidocaine | “IV lidocaine” NCT01319682 ↗ |
| Known as | IVL | “Intravenous lidocaine (IVL), an alternative to epidural analgesia (EA) for laparotomies, has demonstrated anti-inflammatory and anti-hyperalgesic effects.” PMID 41790838 ↗ Mar 20262“Randomisation will be into group Control (C) and Lidocaine (IVL).” NCT03410836 ↗ “perioperative intravenous lidocaine (IVL)” NCT05541640 ↗ |
| Known as | Jetokain | “Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL)...” NCT07145879 ↗ |
| Known as | Jetokain Simplex | “A total of 0.3 mL of Lidocaine Hydrochloride (20 mg/mL, Jetokain Simplex, ADEKA, Samsun, Türkiye) was injected into each trigger point.” NCT07676799 ↗ |
| Known as | L5%P | “Lidocaine transdermal patch (L5%P) is a local anesthetic medication with analgesic effect.” NCT05866653 ↗ |
| Known as | Lambdalina | “Lambdalina® (Lidocaine 4% cream)” NCT01360749 ↗ |
| Known as | LG4 | “topical anesthesia is provided by lidocaine gel 4% (LG4)” NCT01145326 ↗ |
| Known as | LID | “Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.” NCT06907277 ↗ |
| Known as | Lido-Patch | “This study investigated the efficacy of the Lido-Patch (lidocaine 5% medicated plaster) in treatment of pain caused by PHN” NCT03745404 ↗ |
| Known as | lidocain | “Intravenous lidocain during the perioperative period has many beneficial effects in open procedures, such as an earlier return of gastrointestinal tract function, less...” NCT04987372 ↗26“At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will...” NCT05195177 ↗ “Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml.” NCT02580630 ↗ “A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml.” NCT03804008 ↗ “1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin.” NCT01945749 ↗ “The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.” NCT03475641 ↗ “For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.” NCT02700906 ↗ “High Volume Image-Guided Injection with a saline/lidocain solution” NCT02996409 ↗ “1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca)” NCT03535896 ↗ “Drug: Lidocain” NCT07084753 ↗ |
| Known as | Lidocain hydrochloride | “Lidocain hydrochloride 2 % with epinephrine” NCT05101785 ↗ |
| Known as | lidocaine (2% Persocaine-E; Daroupakhsh, Tehran, Iran) | “lidocaine (2% Persocaine-E; Daroupakhsh, Tehran, Iran)” NCT03531970 ↗ |
| Known as | Lidocaine (without epinephrine) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576508 ↗ |
| Known as | Lidocaine 1% Injectable Solution | “Drug: Lidocaine 1% Injectable Solution” NCT06974019 ↗2“Drug: Lidocaine 1% Injectable Solution” NCT04645823 ↗ “Lidocaine 1% Injectable Solution” NCT04505280 ↗ |
| Known as | Lidocaine Gel | “Drug: Lidocaine Gel” NCT01837628 ↗ |
| Known as | Lidocaine HCI | “Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent.” NCT04787731 ↗ |
| Known as | Lidocaine HCl | “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗16“will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.” NCT01552096 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation” NCT05737121 ↗ “Lidocaine Hcl spray (Xylocaine 10% Oral ) will be utilized to the research group” NCT04246255 ↗ “6.5 ml of 2% lidocaine (Lidocaine HCL -Sunny Pharmaceutical)” NCT07205757 ↗ “30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN” NCT01355588 ↗ “Local infiltration with Lidocaine HCL 1%'Debocaine'” NCT05850455 ↗ “Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗ “20 mg Lidocaine HCl+0.0125 mg epinephrine/ml” NCT02007408 ↗ “Lidocaine HCl 2% (200mg/10ml) 10 ml.” NCT02129270 ↗ “2% Lidocaine HCl topical solution” NCT04810494 ↗ “Lidocaine HCl Gel 2%” NCT03560349 ↗ “Drug: Lidocaine HCl” NCT02597257 ↗ “1% Lidocaine HCL” NCT05707208 ↗ “Lidocaine HCl” NCT02264795 ↗ |
| Known as | Lidocaine HCl 1%, USP | “This new formulation ST-CP is injected into the spermatic cord of patients in a very comparable way that the currently available lidocaine solution (Lidocaine HCl 1% USP) is...” NCT04026945 ↗ |
| Known as | Lidocaine HCl 2% | “Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body...” NCT05103215 ↗ |
| Known as | Lidocaine hydrochloride | “The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%...” NCT01027611 ↗103“The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine...” NCT02591199 ↗ “Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered...” NCT06916650 ↗ “The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗ “20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be...” NCT05415865 ↗ “For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.” NCT05178849 ↗ “will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.” NCT05134181 ↗ “Lidocaine Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to maintain local anesthesia throughout the procedure.” NCT03595449 ↗ “1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block.” NCT04491474 ↗ “2% Lidocaine Hydrochloride jelly (Akorn, Buffalo Grove, IL) or Surgilube (Fougera, Melville, NY) using computer generated blocks of 10.” NCT00883103 ↗ “A total of 0.3 mL of Lidocaine Hydrochloride (20 mg/mL, Jetokain Simplex, ADEKA, Samsun, Türkiye) was injected into each trigger point.” NCT07676799 ↗ “1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)” NCT04143165 ↗ “Subconjunctival injection of lidocaine hydrochloride 2% administered after topical proparacaine and prior to intravitreal injection.” NCT07456826 ↗ “group 1 receiving lidocaine hydrochloride, 2%, with 1:100 000 epinephrine and group 2, lidocaine, 2%, with 1:200 000 epinephrine.” PMID 19841339 ↗ Oct 2009 “Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients.” NCT03189329 ↗ “Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%” NCT02825095 ↗ “Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.” NCT03666299 ↗ “Each ml of solution contains 20 mg lidocaine hydrochloride (monohydrate form), corresponding to 16.22 mg lidocaine.” NCT07076641 ↗ “31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)” NCT00483717 ↗ “Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%” NCT00953199 ↗ “single intranasal dose of 30 mg ketorolac tromethamine with 4%, 5% or 6% lidocaine hydrochloride” NCT01355588 ↗ “Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.” NCT03797703 ↗ “The approved investigational product is Lidocaine Hydrochloride Oral Topical Solution 2% USP.” NCT05854082 ↗ “Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)” NCT01567605 ↗ “Lidocaine hydrochloride 20 mg/mL, solution, 20 mL ampoule for intravenous administration” NCT07274254 ↗ “Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization” NCT04571879 ↗ “2% lidocaine hydrochloride with 1:100,000 epinephrine submucosal injection” NCT01302483 ↗ “6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine” NCT06450028 ↗ “using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg)” NCT06226415 ↗ “Lidocaine (2% lidocaine hydrochloride, Pharco, Egypt)” NCT07401745 ↗ “Lidocaine hydrochloride 2% with epinephrine 1:100 000” NCT05944341 ↗ “Lidocaine Hydrochloride 1% Solution for Injection_#2” NCT05210192 ↗ “Lidocaine Hydrochloride 2 mg/mL Injectable Solution” NCT03526874 ↗ “lidocaine hydrochloride 2% and epinephrine 1:100000” NCT04061265 ↗ “Lidocaine hydrochloride ophthalmic gel 3.5%” NCT02955524 ↗ “Local Anesthesia (lidocaine hydrochloride)” NCT06874244 ↗ “Drug: Lidocaine Hydrochloride, Injectable” NCT05369650 ↗ “* Lidocaine hydrochloride 1% 10 ml” NCT00317070 ↗ “Drug: Lidocaine hydrochloride” NCT07054801 ↗ “Drug: Lidocaine Hydrochloride” NCT04906889 ↗ “Drug: Lidocaine Hydrochloride” NCT06328205 ↗ “Drug: Lidocaine Hydrochloride” NCT02953210 ↗ “Drug: Lidocaine Hydrochloride” NCT04409964 ↗ “Drug: Lidocaine Hydrochloride” NCT04524130 ↗ “Drug: Lidocaine Hydrochloride” NCT04732104 ↗ “Drug: Lidocaine Hydrochloride” NCT03921567 ↗ “Drug: Lidocaine Hydrochloride” NCT03854344 ↗ “Drug: Lidocaine hydrochloride” NCT06462781 ↗ “Drug: Lidocaine Hydrochloride” NCT06301685 ↗ “Drug: Lidocaine hydrochloride” NCT03310970 ↗ “0.5% Lidocaine Hydrochloride” NCT06201039 ↗ “Lidocaine Hydrochloride 2%” NCT03399474 ↗ “lidocaine hydrochloride” NCT04880928 ↗ “Lidocaine hydrochloride” NCT02293447 ↗ |
| Known as | lidocaine hydrochloride (Xylocaine) | “lidocaine hydrochloride (Xylocaine)” NCT04364425 ↗2“lidocaine hydrochloride (Xylocaine)” NCT02708693 ↗ “lidocaine hydrochloride (Xylocaine)” NCT03072290 ↗ |
| Known as | Lidocaine Hydrochloride ampule | “Lidocaine Hydrochloride ampule” NCT03921567 ↗ |
| Known as | Lidocaine Hydrochloride Injection USP | “Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)” NCT05193227 ↗ |
| Known as | Lidocaine hydrochloride topical solution, USP, 4% | “Lidocaine hydrochloride topical solution, USP, 4%” NCT05890495 ↗ |
| Known as | Lidocaine Hydrochloride, Injectable | “Drug: Lidocaine Hydrochloride, Injectable” NCT04295330 ↗ |
| Known as | Lidocaine hydrocholoride | “3. Lidocaine hydrocholoride buffered alone” NCT02591199 ↗ |
| Known as | Lidocaine in Saline | “Drug: Lidocaine in Saline” NCT06792474 ↗ |
| Known as | Lidocaine Injectable Solution | “Drug: Lidocaine Injectable Solution” NCT06872437 ↗ |
| Known as | Lidocaine injection | “Drug: Lidocaine injection” NCT03140293 ↗ |
| Known as | Lidocaine liposomal 4% | “Maxilene® (Lidocaine liposomal 4%)” NCT02616419 ↗ |
| Known as | Lidocaine patch | “Lidocaine patch” NCT04238208 ↗ |
| Known as | Lidocaine Patch 5% | “Commercially available Lidoderm® (lidocaine patch 5%)” NCT00903851 ↗1“Lidocaine patch 5%” NCT00904397 ↗ |
| Known as | Lidocaine Spray | “Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will...” NCT04859738 ↗ |
| Known as | Lidocaine topical | “Drug: Lidocaine topical” NCT04732104 ↗ |
| Known as | Lidocaine topical aerosol | “This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.” NCT03362905 ↗ |
| Known as | Lidocaine topical system 1.8% | “Lidocaine topical system 1.8%” NCT04144192 ↗ |
| Known as | Lidocaine Viscous | “Lidocaine Viscous” NCT06185933 ↗ |
| Known as | lidocainhydrochlorid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02456597 ↗ |
| Known as | Lidocaïne Aguettant | “Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.” NCT05032508 ↗ |
| Known as | Lidoderm | “Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.” NCT00904020 ↗14“Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response?” NCT01086150 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back” NCT00904397 ↗ “Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)” NCT00904111 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)” NCT00904605 ↗ “Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain” NCT00904202 ↗ “a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.” NCT01688518 ↗ “5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm” NCT04238208 ↗ “three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA).” NCT04506034 ↗ “Commercially available Lidoderm (lidocaine patch 5%) was provided to patients” NCT00904540 ↗ “Patients will receive Lidoderm topical 5% lidocaine patches.” NCT03120351 ↗ “Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.)” NCT00904462 ↗ “Lidoderm” NCT02749123 ↗ |
| Known as | lidokaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448316 ↗ |
| Known as | LidotopⓇ | “pretreatment with a 5% lidocaine patch (LidotopⓇ) (Group A)” NCT05732181 ↗ |
| Known as | lignocaine | “mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint.” NCT07102225 ↗66“Lignocaine is a local anaesthetic agent, which is also commonly used as a perioperative analgesic adjunct to accelerate rehabilitation and enhance recovery after surgery.” PMID 28683817 ↗ Jul 2017 “The aim of this study is to investigate the beneficial effects of intravenous lignocaine on reducing pain, nausea and vomiting after laparoscopic cholecystectomy.” NCT04182828 ↗ “lignocaine spray (LOX 10% spray, Neon laboratories LTD, Thane, India) will be used over vocal cords prior to intubation to blunt the sympathetic stimulation.” NCT03013075 ↗ “Lidocaine (Xylocaine), also called lignocaine, is a potent local anesthetic agent, widely used both topical and injection anesthesia.” NCT03265197 ↗ “Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine.” NCT02304094 ↗ “5% lidocaine (lignocaine) medicated plaster or pregabalin as first-line therapy for relief of peripheral neuropathic pain.” PMID 19301937 ↗ 2009 “Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).” NCT03240783 ↗ “A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit” NCT06150794 ↗ “one under complete intravenous anesthesia (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine)” NCT06390046 ↗ “Topical lignocaine is administered during bronchoscopy for local anaesthesia.” NCT02981277 ↗ “The most frequently used drug to alleviate POPI is intravenous lignocaine.” NCT05486819 ↗ “0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic” NCT05599971 ↗ “Emla 5% cream (Lignocaine 2.5% / Prilocaine 2.5%)” NCT01847157 ↗ “1-2 ml of 1% lignocaine for skin infiltration” NCT03422354 ↗ “5% lidocaine [lignocaine] medicated plaster” PMID 19432499 ↗ 2009 “Lignocaine, Xylocaine, Ztlido (lidocaine)” NCT05086224 ↗ “2 ml lignocaine 2%” NCT05837494 ↗ “1% lignocaine” NCT04798391 ↗ |
| Known as | lignocaine HCl | “During nasal pack removal, the subjects will be randomly divided into 2 groups: the Lignocaine group (2% lignocaine HCl) and the Normal saline group (0.9% NaCl) using simple...” NCT03602287 ↗ |
| Known as | lignocaine hydrochloride | “The conventional 2% lignocaine will be commercially available 2% lignocaine hydrochloride with 1:200,000 epinephrine, while the pre-warmed solution will be heated in a...” NCT06806202 ↗3“Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg...” NCT03944655 ↗ “The patients received pre-ovulatory pertubations with lignocaine hydrochloride 10 mg (n = 16) or ringer acetate (placebo, n = 9).” PMID 23921822 ↗ Sep 2013 “After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine” NCT02831374 ↗ |
| Known as | lignospan | “Lidocaine (known as lignospan commercially)” NCT06450028 ↗ |
| Known as | Liposomal Lidocaine | “Liposomal lidocaine 4% cream (Maxilene, RGR Pharma, Windsor, Ontario) is another anaesthetic cream” NCT00353002 ↗ |
| Known as | LL30 | “In the early 1940s, Nils Lofgren discovered lidocaine as a potent anesthetic, initially labelled LL30.” NCT03095404 ↗ |
| Known as | LMP | “5% lidocaine-medicated plaster (LMP), which can block the Na+ channels on Aδ and C fibres” PMID 34341037 ↗ Aug 2021 |
| Known as | LMX | “Lidocaine Topical Cream [LMX]” NCT03187392 ↗ |
| Known as | LMX 4 (Lidocaine 4%) | “LMX 4 (Lidocaine 4%)” NCT01842373 ↗ |
| Known as | LMX4 | “Lidocaine 4% Topical Application Cream [LMX 4]” NCT03526874 ↗1“LMX4 (Lidocaine 4%)” NCT01842373 ↗ |
| Known as | LP5 | “5% lidocaine plaster (LP5) is recommended for localized neuropathic pain” PMID 31009419 ↗ May 2019 |
| Known as | Maxilene | “Liposomal lidocaine 4% cream (Maxilene, RGR Pharma, Windsor, Ontario) is another anaesthetic cream” NCT00353002 ↗1“Maxilene® (Lidocaine liposomal 4%)” NCT02616419 ↗ |
| Known as | Nebulized Xylocaine | “Nebulized Xylocaine” NCT04571879 ↗ |
| Known as | ORE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05923086 ↗ |
| Known as | Platelet Rich Plasma (PRP) | “Application of autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of non-healing and diabetic foot ulcers, as it is an easy and...” PMID 28241824 ↗ Feb 2017 |
| Known as | PowderJect Dermal Lidocaine | “ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗ |
| Known as | PowderJect(R) Dermal Lidocaine | “ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia to provide within 1-3 minutes painless needle or cathether insertion for blod drawing.” NCT00140088 ↗1“ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia within 3 minutes to provide painless needle or cathether insertion for blood drawing.” NCT00146185 ↗ |
| Known as | Pridocaine | “This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.” NCT03362905 ↗ |
| Known as | Promescent Lidocaine Spray | “Promescent Lidocaine Spray is a non-prescription drug that is marketed under an over-the-counter drug monograph (21 CFR Section 348.10 Subpart B (a)(2)) for male genital...” NCT02241460 ↗ |
| Known as | Proxicam | “The Effectiveness of Mesotherapy (Lidocaine and Proxicam) in the Treatment of Chronic Migraine” NCT06118190 ↗ |
| Known as | PRP | “PRP, which comes from the patient's own blood and is thought to reduce inflammation and promote healing.” NCT06998433 ↗1“Platelet rich plasma (PRP)” NCT07535190 ↗ |
| Known as | Rapidocain(R) | “Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine” NCT01807962 ↗ |
| Known as | Salonpas | “Salonpas (Lidocaine Patch 4%)” NCT05106400 ↗ |
| Known as | ST-01 | “The new formulation ST-01 is a sustained release lidocaine formulation” NCT05193227 ↗ |
| Known as | Topicaine | “topical lidocaine gel (Topicaine)” NCT00382083 ↗ |
| Known as | Topical Lidocaine | “Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms” NCT02832115 ↗ |
| Known as | Vemcain Spray | “lidocaine spray (Vemcain® Spray)” NCT06885723 ↗ |
| Known as | Versatis (Trade Mark) | “Versatis (Trade Mark)” NCT03765697 ↗ |
| Known as | Viscous lidocaine | “Viscous lidocaine” NCT04515901 ↗ |
| Known as | Xylocain | “2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.” NCT03871465 ↗ |
| Known as | xylocaina | “with an association of betamethasone dipropionate, betamethasone disodium phosphate {diprospan®}, plus lidocaine (xylocaina®).” NCT03196817 ↗ |
| Known as | Xylocaine | “Participants will be randomized using computer generated allocation to receive 10% Xylocaine (lidocaine group) spray or normal saline 0.9% (placebo group), applied identically...” NCT02097017 ↗64“In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60...” NCT04050059 ↗ “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ “Lidocaine (Xylocaine) has a better pharmacokinetic and pharmacodynamics profile than levobupivacaine and is also widely used as local anaesthetic agent in clinical practice.” NCT04397484 ↗ “will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.” NCT01552096 ↗ “10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance” NCT01995461 ↗ “Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.” NCT06176248 ↗ “Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.” NCT02314546 ↗ “Lidocaine Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to maintain local anesthesia throughout the procedure.” NCT03595449 ↗ “The steroid injection was using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine).” NCT02708693 ↗ “The use of Lidocaine spray (Xylocaine 10%) is commonly available worldwide and is routinely used in our institution before fiberoptic laryngoscopy.” NCT04519463 ↗ “Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000” NCT04919421 ↗ “ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)” NCT04346030 ↗ “Experimental group: will receive 6cc of 2 lidocaine gel (Xylocaine) administered vaginally before paracervical block for IUD placement” NCT06974032 ↗ “Lidocaine (Xylocaine), also called lignocaine, is a potent local anesthetic agent, widely used both topical and injection anesthesia.” NCT03265197 ↗ “Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)” NCT04980105 ↗ “Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days” NCT01205477 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine” NCT07692009 ↗ “five drops of lidocaine hydrochloride (Xylocaine 2%, 20 mg/ml; AstraZeneca, London, UK) using a prefilled dropper” NCT05738564 ↗ “Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)” NCT05193227 ↗ “The local anesthetic used in all cases was a mixture of 10 ml of 2% xylocaine and 10 ml of 0.5% bupivacaine.” NCT07299877 ↗ “A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).” NCT03600454 ↗ “Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively” NCT04148599 ↗ “A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.” NCT02049879 ↗ “To determine if a Xylocaine jelly (2% infused lidocaine) decreases pain with paracervical block” NCT06960317 ↗ “Group A:The study group will be given topical Xylocaine (2% Lidocaine) before the procedure.” NCT03802032 ↗ “plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections” NCT04019782 ↗ “Use of a local anesthetic(" xylocaine 1%") for the realization of scalp nerve block” NCT03666949 ↗ “A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.” NCT02577510 ↗ “Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)” NCT05861570 ↗ “0.5ml of Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000)” NCT06694714 ↗ “30 ml vial of lignocaine 2% (20 mg/ml Xylocaine, AstraZeneca, India)” NCT04850885 ↗ “Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine” NCT00465439 ↗ “Xylocaine (lidocaine) 2% and Xylocard (lidocaine) 10%” NCT05072314 ↗ “Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗ “2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine” NCT06165939 ↗ “Lignocaine, Xylocaine, Ztlido (lidocaine)” NCT05086224 ↗ “Meso-Jet, 2% lidocaine(xylocaine)” NCT04493528 ↗ “4ml 2% xylocaine” NCT02776865 ↗ “Drug: Xylocaine” NCT04901065 ↗ |
| Known as | Xylocaine - MPF | “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗1“Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗ |
| Known as | Xylocaine 1% | “1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt)” NCT02522130 ↗ |
| Known as | Xylocaine 10% Oral | “Lidocaine Hcl spray (Xylocaine 10% Oral ) will be utilized to the research group” NCT04246255 ↗ |
| Known as | Xylocaine 10% pump spray | “Lidocaine spray 10 % (Xylocaine 10% pump spray; AstraZeneca BV, Zoetermeer, The Netherlands)” NCT06354816 ↗ |
| Known as | Xylocaine 2 % | “5 mL of 2 % viscous lidocaine solution (20 mg/mL) (Xylocaine 2 %, Astra Zeneca, London, UK)” NCT06185933 ↗ |
| Known as | xylocaine AstraZeneca | “1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)” NCT04143165 ↗ |
| Known as | Xylocaine Jelly | “A syringe consists of six millimeters of two percent lidocaine gel (Xylocaine Jelly, AstraZeneca, Australia) for the active management group” NCT06864078 ↗ |
| Known as | Xylocaine spray | “Xylocaine spray” NCT04901065 ↗ |
| Known as | Xylocaine, Lidocaine Hydrochloride | “Xylocaine, Lidocaine Hydrochloride” NCT02595463 ↗ |
| Known as | Xylocaine, lidocaine hydrochloride (HCl) Injection | “Xylocaine, lidocaine hydrochloride (HCl) Injection” NCT05378113 ↗ |
| Known as | Xylocard | “Xylocaine (lidocaine) 2% and Xylocard (lidocaine) 10%” NCT05072314 ↗ |
| Known as | ZTlido | “The objectives of this study are to evaluate the adhesion performance and pharmacokinetics of ZTlido (lidocaine topical system) 1.8% during swimming, showering, and under...” NCT04784728 ↗4“ZTlido™ Lidocaine Topical System 1.8% (36 mg) Versus Lidoderm® Lidocaine Patch 5% (700 mg)” PMID 32606914 ↗ Jun 2020 “ZTlido 1.8% lidocaine patch application to both feet for 7 days up to 12 hours per day.” NCT06030297 ↗ “ZTlido (Lidocaine Topical System) 1.8%” NCT05106400 ↗ |
| Known as | Ztlido (lidocaine) | “Lignocaine, Xylocaine, Ztlido (lidocaine)” NCT05086224 ↗ |
| Action | Inhibit | “Lidocaine is a class I (sodium channel block) antiarrhythmic drug.” NCT00587483 ↗ |
| Modality | Other / unclassified | “local anesthetic” NCT00863889 ↗ |
| Route | Topical | “S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)” NCT00107835 ↗ |
| Target | TRPV1 | “use lidocaine as the TRPV1 agonist” NCT06302257 ↗ |